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The	central	aim	of	Personalized	Medicine	 is	 to	exploit	 the	 individual’s	genomic	























2015,	 the	 newest	 term	 “Precision	Medicine”	was	 introduced	 by	 former	 US	 President	
Barack	H.	Obama,	who	announced	the	US	Precision	Medicine	Initiative	(PMI).		
While	 there	 are	 many	 definitions	 of	 the	 term,	 the	 concept	 of	 personalized	
medicine	involves	the	combined	knowledge	of	genetics	to	predict	disease	susceptibility,	
disease	prognosis,	 or	 treatment	 response	of	 a	person	 to	 improve	 the	person’s	health.	





practice,	 particularly	 as	 they	 are	 operating	 within	 an	 increasingly	 budget-scarce	
environment.	 It	 is	 often	 argued	 that	 personalizing	 treatment	 will	 inevitably	 improve	
clinical	 outcomes	 for	 patients	 and	 help	 achieve	 more	 effective	 use	 of	 health	 care	
resources.	Hence,	demand	is	increasing	for	demonstrable	evidence	of	clinical	utility	and	
cost-effectiveness	 to	 support	 the	 use	 of	 personalized	 medicine	 in	 health	 care.	
(Shabaruddin	et	al.,	2015).	
Pharmacogenomics	is	a	core	component	of	Personalized	Medicine	and	as	such,	it	







Pharmacogenetics	 is	 a	 term	 that	 refers	 to	 the	 study	 of	 the	 effect	 of	 genomic	
variations	on	drug	response,	in	terms	of	both	drug	metabolism	(pharmacokinetics)	and	
drug	 action	 (pharmacodynamics).	 Additionally,	 genetic	 variants	 have	 been	 shown	 to	
explain	what	had	previously	been	considered	to	be	idiosyncratic	adverse	drug	reactions	
(ADR).	 In	other	words,	 this	discipline	aims	to	 identify	 the	best	medicine	 for	a	specific	
disease	 when	 the	 disease	 occurs	 in	 a	 patient	 population	 with	 a	 particular	 genotype.	
Considering	 the	 fact	 that	 there	 are	 genetic	 factors	 that	 account	 for	 20-95%	 of	 the	
observed	responses	to	drug	therapies	(Squassina	et	al.,	2010),	one	could	understand	the	
impact	 of	 this	 new	 discipline	 in	modern	medicine.	 It	 is	 important	 to	 note	 that	 other	







treatment	 interventions,	 in	 comparison	 with	 the	 standard	 interventions	 used	 in	 the	






into	 practice.	 Furthermore,	 in	 this	 thesis,	 we	 investigated,	 through	 structural	
questionnaires,	the	views,	opinions	and	attitudes	of	the	various	stakeholders	and	of	the	
general	public	about	genomic	medicine	and	its	impact	to	society.	Lastly,	we	proposed	an	
alternative	 methodological	 approach	 for	 cost-effectiveness	 analysis	 and	 developed	 a	
practical	guidance	for	decision	making	by	budget	holders.	
In	 Chapter	 2,	 we	 provide	 some	 key	 examples	 of	 the	 applications	 of	
pharmacogenetics	in	modern	medical	practice,	focusing	on	different	medical	specialties	
such	 as	 cardiology,	 oncology,	 psychiatric	 and	 infectious	 diseases	 and	 of	 these	
interventions	 that	have	been	approved	by	all	major	regulatory	bodies,	 such	as	 the	US	
Food	and	Drug	Administration	(FDA)	and	the	European	Medicines	Agency	(EMA).	Also,	
we	 emphasize	 the	 need	 to	 perform	 economic	 evaluation	 and	 its	 different	 types,	
summarize	the	main	methodological	aspects	of	economic	evaluation	and	outline	the	few	
examples	of	economic	evaluation	in	genomic	medicine	that	have	been	performed	so	far.	
At	 first,	we	 aimed	 to	 determine	 the	 level	 of	 awareness	 of	 healthcare	 professionals	 in	
Greece	with	respect	 to	pharmacogenetics	and	personalized	medicine	using	structured	
questionnaires	 addressed	 to	 a	 large	 number	 of	 pharmacists	 and	 physicians.	 These	
findings	are	presented	in	Chapter	3.		
In	 Chapter	 4,	 we	 sought	 to	 enrich	 our	 understanding	 over	 the	 policies	 and	
opinions	of	the	key	stakeholders	involved	in	the	translation	of	genomic	findings	in	the	
clinic.	 To	 achieve	 our	 goals,	 we	 used	 the	 computerized	 version	 of	 the	 PolicyMaker	
political	 mapping	 tool	 to	 collect	 and	 organize	 important	 information	 about	 the	
pharmacogenetics	 and	 genomic	 medicine	 policy	 environment,	 to	 assess	 the	 policy’s	
content,	the	major	players,	their	power	and	policy	positions,	their	interests	and	networks	
and	coalitions	that	interconnect.	
In	 Chapter	 5,	 we	 present	 our	 findings	 from	 a	 prospective	 study	 to	 perform	
economic	evaluation	of	genome-guided	warfarin	treatment	in	elderly	Croatian	patients	
suffering	 from	 atrial	 fibrillation,	 indicating	 that	 genome-guided	warfarin	 treatment	 is	
cost-effective.	
Similar	 to	 the	 previous	 chapter,	 in	 Chapter	 6,	 we	 report	 our	 findings	 from	 a	
retrospective	study	to	assess	whether	CYP2C19-guided	genotyping	was	cost-effective	for	
myocardial	infarction	patients	receiving	clopidogrel	treatment	in	the	Serbian	population	




treatment	 coupled	 with	 CYP2C19-guided	 genotyping	 may	 represent	 a	 cost-saving	
approach	 for	 the	 management	 of	 myocardial	 infarction	 patients	 undergoing	 primary	
percutaneous	coronary	intervention	in	Serbia.	
In	Chapter	7,	we	propose	the	Genome	Economics	Model	(GEM),	which	is	a	public	
health	 genomics-driven	 approach	 to	 adjust	 the	 classical	 healthcare	 decision	 making	
process	with	an	alternative	methodological	approach	of	cost-effectiveness	analysis.	 In	
particular,	we	combine	the	classical	cost-effectiveness	analysis	with	budget	constraints,	
social	preferences	and	patient	ethics.	This	model	provides	 the	rationale	 to	ensure	 the	
sustainability	of	funding	for	genome-guided	interventions,	their	adoption	and	coverage	
by	 health	 insurance	 funds,	 and	 prioritization	 of	 the	 Genomic	 Medicine	 research,	
development	 and	 innovation,	 especially	 in	 those	 countries	 with	 budget	 restrictions,	






































































It	 has	 been	 known	 for	 decades	 that	 substantial	 inter-individual	 variability	 can	









in	 0.32%	of	 patients	 (Davies	 et	 al.,	 2007).	 ADRs	 can	 be	 unpredictable,	 and	 a	 broader	
knowledge	of	predisposing	biomarkers	would	greatly	increase	prevention	capabilities.		
It	has	been	shown	that	the	great	heterogeneity	in	the	phenotypic	expression	of	the	
drug	 treatment	 response	 and	 ADRs	 might	 be	 determined	 by	 a	 complex	 interplay	 of	
multiple	genetic	variants	and	environmental	factors	(Squassina	et	al.,	2010).	This,	in	turn,	
increases	 the	 need	 for	 personalized	 prescriptions	 that	 should	 take	 advantage	 of	 the	
creation	 of	 a	 structured	 informational	 framework	 of	 phenotypic,	 environmental	 and	
genetic	 data,	 ultimately	 leading	 to	 the	 reduction	 of	 the	 high	 incidence	 of	 ADRs	 and	
therapeutic	failure.		
Pharmacogenetics	has	been	defined	as	“the	delivery	of	the	right	drug	to	the	right	




molecules	 suitable	 for	 drug-development	 process	 (Squassina	 et	 al.,	 2010).	 Ideally,	
pharmacogenomic	 tests	 would	 be	 proactively	 co-developed,	 together	 with	 new	 drug	
candidates	(Giacomini	et	al.,	2007).	In	this	context,	pharmacogenetics	paves	the	path	to	
personalized	medicine,	which	consists	of	the	implementation	of	genetic	information	to	

















Coumarin	 oral	 anticoagulants	 (COAs),	 such	 as	 warfarin,	 acenocoumarol	 and	
phenprocoumon,	 are	 considered	 standard	 oral	 anticoagulant	 treatment	 for	
thromboembolic	 disorders	 for	 more	 than	 60	 years.	 However,	 COAs	 have	 a	 narrow	

























by	approximately	80%,	when	compared	 to	 the	wild	 type	 CYP2C9*1	allele.	As	a	 result,	
patients	with	a	CYP2C9	*1/*1	genotype	require	a	daily	mean	maintenance	warfarin	dose	
of	 5-7	mg,	 while	 CYP2C9	 *1/*3	 heterozygote	 patients	 require	 lower	 doses	 (3-4	mg).	
CYP2C9*1/*2	heterozygous	patients	should	receive	a	lower	daily	warfarin	dose	(3-4	mg)	
if	they	also	bear	the	VKORC1	c.-1639	A	allele	in	hetero-	or	homozygosity	(Johnson	et	al.,	
2011).	 In	 various	 population	 groups,	 the	 variant	 alleles	 allele	 present	 with	 varying	
frequencies,	with	CYP2C9*2	and	CYP2C9*3	being	more	common	in	European	Americans,	
respectively,	 and	 less	 common	 in	Asians	and	African	Americans.	 In	addition,	 genomic	
variants	 in	 the	 VKORC1	 gene,	 which	 encodes	 the	 production	 of	 vitamin	 K	 epoxide	
reductase,	 have	 also	 been	 shown	 to	 affect	 warfarin	 treatment.	 There	 are	 5	 VKORC1	
variant	 combinations	 (e.g.,	 haplotypes)	 that	 are	 associated	with	 altered	VKORC1	 gene	
expression	 and	 as	 such	 with	 different	 warfarin	 dose	 requirements.	 The	 allelic	
frequencies	 of	 these	 VKORC1	 haplotypes	 also	 vary	 in	 different	 populations.	 The	
combination	 of	 the	 CYP2C9	 and	 VKORC1	 genomic	 variations	 appears	 to	 account	 for	
another	30-40%	of	 inter-individual	dose	variation	 (Flockhart	et	 al.,	 2008).	Remaining	
unexplained	variability	could	be	due	to	other	genetic	variants,	uncharacterized	variants	
in	 other	 genomic	 loci	 as	 well	 as	 other	 personal	 or	 environmental	 factors	 yet	 to	 be	
identified.	Currently	available	warfarin	dosing	calculators	(e.g.,	warfarindosing.org)	use	
a	combination	of	clinical	and	genetic	factors	and	have	been	demonstrated	to	be	superior	
in	 predicting	 the	 stable	 warfarin	 dose	 when	 compared	 to	 clinical	 judgment	 alone	
(Johnson	et	al.,	2011).		
On	average,	one-third	of	 the	population	carries	one	or	both	of	 the	CYP2C9	and	
VKORC1	 genomic	 biomarkers	 that	 are	 shown	 to	 be	 associated	 with	 slower	 warfarin	
metabolism,	 which	 in	 turn	 increases	 the	 likelihood	 of	 over-anticoagulation	 and	 the	
associated	risk	of	serious	bleeding.	It	is	important	to	note	that	individuals	who	are	‘wild	
type’	 require	 slightly	 higher	 warfarin	 doses	 than	 the	 recommended	 starting	 dose	 (6	




regularly	monitoring	 the	anticoagulation	 levels	 through	blood	tests	and	decreasing	or	
increasing	the	warfarin	dose	if	the	international	normalized	ratio	(INR)	is	too	high	or	too	
low,	 respectively.	 As	 such,	 pharmacogenetics	 testing	 could	 potentially	 identify	 the	
patients	that	are	likely	to	present	with	slower	warfarin	metabolism	that	could	influence	
both	the	dose	of	warfarin	as	well	as	the	recommended	timing	of	INR	studies.	This	may	be	





(>65	 years	 old)	 in	 the	 United	 States,	 who	 experienced	 adverse	 reactions	 to	 these	








specific	 instructions	on	how	to	use	genotype	 to	predict	 individualized	doses:	 the	new	
label	 provides	 a	 concise	 table	 of	 dosing	 recommendations,	 stratified	 by	 genotype.	
However,	 to	 date	 the	 FDA	 black	 box	warning	 doesn’t	 require	 that	 pharmacogenetics	
testing	be	done	prior	
	to	 initiation	 of	 Warfarin.	 An	 evidence-based	 practice	 guideline	 for	
pharmacogenetically	 informed	 warfarin	 dosing	 has	 been	 published	 by	 the	 Clinical	
Pharmacogenetics	Implementation	Consortium	(Caudle	et	al.,	2014).	
Another	drug	 that	 is	 the	 standard	 for	 the	 care	of	 acute	 coronary	 syndromes	 is	
clopidogrel.	Non-responsiveness	 to	 clopidogrel	 is	widely	 recognized	 and	 is	 related	 to	
recurrent	 ischemic	 events;	 approximately	 25%	 of	 patients	 receiving	 clopidogrel	
experience	 a	 subtherapeutic	 antiplatelet	 response	 associated	 with	 increased	 risk	 of	
recurrent	 ischemic	 events	 (Gladding	 et	 al.,	 2008).	 Current	 experimental	 evidence	
suggests	that	the	response	to	clopidogrel	may	be	determined	by	the	CYP2C19	genotype	











Individualized	 therapies	 for	 various	 types	 of	 solid	 tumours	 are	 now	 a	 reality.	
Trastuzumab,	a	monoclonal	antibody	(MAb)	blocking	v-erb-b2	erythroblastic	leukaemia	




is	 overexpressed	 in	 approximately	 one-fourth	 of	 breast	 cancer	 patients;	 its	
overexpression	 is	 correlated	 with	 poor	 prognosis,	 increased	 tumour	 formation	 and	
metastasis,	 as	 well	 as	 resistance	 to	 chemotherapeutic	 agents.	 HER2	 testing	





often	 employed	 as	 predictors	 of	 the	 progression-free	 survival	 with	 gefitinib	 in	 a	
comparison	 with	 carboplatin-paclitaxel	 (Mok	 et	 al.,	 2009).	 Another	 study	 has	
demonstrated	the	feasibility	of	genetic	screening	for	EGFR	gene	variants	in	patients	with	
advanced	 Non-Small-Cell	 Lung	 Cancer	 (NSCLC)	 for	 the	 selection	 of	 patients	 that	 are	
eligible	for	erlotinib	therapy	(Rosell	et	al.,	2009).	Taken	together,	these	reports	suggest	














In	 addition	 to	K-ras,	 increases	 in	EGFR	 gene	 copy	number	have	been	 correlated	with	
tumour	response	rate	(Sartore-Bianchi	et	al.,	2007).		
Irinotecan	is	another	drug	that	has	been	approved	for	the	treatment	of	advanced	
colorectal	 cancer	 and	 with	 limiting	 adverse	 reactions,	 such	 as	 diarrhoea	 and	 severe	
neutropenia.	 The	 UGT1A1*28	 polymorphism,	 characterized	 by	 the	 presence	 of	 an	
additional	TA	repeat	in	the	TATA	sequence	of	the	UGT1A1	gene	promoter,	([TA]7,	instead	
of	 [TA]6;	 (Iyer	 et	 al.,	 2002)),	 is	 associated	with	 reduced	UGT1A1	 gene	expression	and	
decreased	glucuronidation	of	the	active	metabolite	SN-38,	resulting	in	increased	toxicity	




The	 antileukemics	 6-mercaptopurine	 and	 6-thioguanine,	 along	 with	 the	






associated	 with	 TPMT	 deficiency.	 Concordance	 between	 genotype	 and	 phenotype	














Pharmacogenetics	 for	 infectious	diseases	 is	an	expanding	area	that	 is	gradually	






carbocyclic	 nucleoside	 analogue	 with	 inhibitory	 activity	 against	 human	
immunodeficiency	virus	(HIV-1).	It,	 in	combination	with	other	antiretroviral	agents,	 is	








about	 this	 and	 information	 was	 added	 to	 the	 boxed	 warning	 [FDA,	 2014].	 Also,	 the	






The	 identification	 of	 key	 phenotypic	 measures	 of	 response	 to	 psychotropic	




personalized	medicine	 is	 still	 far	 from	being	achieved	 in	 the	 field	of	psychiatry	 (Alda,	
2013).		





response	 to	 it	 or	 to	 clozapine	 (reviewed	 in	 Tsermpini	 et	 al.,	 2013).	 In	 addition	 to	
predicting	 metabolic	 capacity,	 genotyping	 of	 the	 CYP2D6	 gene	 can	 also	 assist	 health	
professionals	 in	 the	 decisional	 process	 of	 identifying	 those	 patients	 who	 need	 to	 be	
monitored	for	serum	levels	or	for	the	possible	onset	of	ADRs.	A	number	of	findings	have	
also	shown	that	CYP2D6	genetic	variants	correlate	with	serum	levels	of	risperidone	and	






of	 pharmacogenomic	 studies	 have	 focused	 on	 serotonin	 system	 genes	 reporting	
significant	 association	 for	 the	 5-HTTLPR	 polymorphism	 of	 the	 serotonin	 transporter	
(SLC6A4)	 gene	 [81-88]	 as	 well	 as	 for	 polymorphisms	 in	 HTR2A	 and	 HTR1A	 genes	
(reviewed	in	Squassina	et	al.,	2010).		





association	 studies	 (GWAS)	 of	 lithium	 treatment	 response	 identified	 few	 genetic	



































(d) The	 extended	 average	 lifespan.	 Usually,	 older	 people	 suffer	 from	 multiple	
conditions	and	chronic	diseases,	with	higher	treatment	costs,	
(e) The	public’s	expectations.	It	is	the	expressed	conviction	of	a	democratic	state	that	
the	 citizens’	 needs	 must	 be	 met	 with	 no	 particular	 consideration	 to	 the	 cost.	
Furthermore,	 the	 citizens’	 demands	 have	 increased,	 thanks	 to	 the	 improved	





Because	 all	 of	 these	 factors	 constitute	 a	 direct	 or	 indirect	 financial	 burden	 in	
modern	health	care	systems,	governments	believe	that	the	money	spent	for	health	care	
is	excessive	and	that	priorities	must	be	set,	or	the	ratio	at	which	the	state	and	the	patient	







available	 resources	 in	 such	 a	 way	 to	 achieve	 the	 best	 possible	 level	 of	 health	 of	 the	
population,	based	on	certain	societal	criteria.	In	certain	cases,	such	criteria	may	lead	to	
an	 increase	 in	 expenditures	 when	 this	 is	 financially	 viable	 or	 socially	 acceptable	
(Fragoulakis	et	al,	2015).	If	the	ultimate	goal	were	to	reduce	expenditures,	then	the	state	
would	 simply	 cease	 to	 provide	 health	 care	 services	 to	 certain	 citizens,	 which	 would	
achieve	immediate	savings	but	would	inflame	the	public	sense	of	justice	and	would	strain	















Cost–benefit	 analysis	 (CBA):	A	method	of	 comparing	 the	 costs	 and	 the	money-valued	
benefits	of	various	alternative	courses	of	actions.		Systematic	comparison	of	all	these	
relevant	 costs	 and	 benefits	 of	 proposed	 alternative	 schemes	 with	 a	 view	 to	





analysis	 except	 that	 the	 benefit	 instead	 of	 being	 expressed	 in	 monetary	 terms	 is	
expressed	in	clinical	result	achieved	(e.g.,	life	years	gained).	For	instance,	these	can	
be	 the	 number	 of	 lives	 saved	 or	 number	 of	 days	 free	 from	 the	 symptoms	 of	 the	
disease.	There	may	be	units	that	are	specific	to	the	procedures	being	compared,	such	
as	 the	 speed	 of	 a	 healing	 wound	 or	 generic,	 such	 as	 Quality-Adjusted	 Life	 Years	
(QALY),	 thus	 enabling	 comparisons	 of	 cost-effectiveness	 to	 be	made	 across	many	
different	 technologies	 in	 different	 disciplines	 and	 patient	 groups	 (Ramsey	 et	 al,	
2015).	This	type	of	analysis	is	most	frequently	used	in	the	economic	evaluation	of	the	
health	care	technologies	and	was	also	used	in	Chapters	4	and	5	of	this	thesis.	


















If	 a	 standard	 health	 technology	 or	 intervention	 that	 is	 currently	 used	 by	 the	































The	 ICER	 is	 intended	 primarily	 to	 provide	 information	 during	 the	 decision-
making	process	in	the	case	of	more	expensive	and	more	effective	treatments,	which	is	
the	most	common	scenario.	Nevertheless,	the	ICER	calculation	by	itself	does	not	allow	
conclusions	 to	 be	 drawn	 about	 the	 cost-effectiveness	 of	 the	 various	 options.	 Such	








2005,	 Birch	 et	 al,	 2006;	 Sendi	 et	 al,	 2002;	 Waillo	 et	 al,	 2009).Indeed,	 even	 large	
organisations	such	as	the	UK	National	 Institute	 for	Health	and	Care	Excellence	(NICE)	






£60,000	 is	 the	 maximum	 accepted	 value	 in	 most	 cases.	 A	 value	 between	 $50,000-
$100,000	is	considered	cost-effective,	a	value	below	€20,000	is	considered	particularly	






















etc,	 then	 a	 cost-benefit	 analysis	 must	 be	 performed	 in	 order	 to	 determine	 all	 the	
consequences	of	the	relevant	options.	If,	in	other	case,	the	analysis	focuses	on	distributing	
resources	 between	 different	 sectors	 of	 health	 care	 (prevention,	 treatment,	 etc.)	 or	
between	 different	 interventions	 for	 the	 treatment	 of	 a	 specific	 condition,	 then	 the	
consequences	to	be	measured	will	be	more	limited.	The	selection	of	analysis	method	is	
also	 affected	 by	 the	 person	 or	 institution	 (patient,	 hospital,	 insurance	 carrier,	 etc.)	
performing	 the	analysis	and	by	 the	availability	of	 relevant	data.	 In	practice,	economic	
evaluation	is	used	for	analyses	for	alternative	interventions	within	a	disease	and	less	for	
interventions	 involving	 different	 sectors	 of	 the	 economy.	 For	 example,	 if	 the	 study	










§ Direct	 healthcare	 costs:	 the	 cost	 caused	 by	 healthcare	 suppliers	 (the	 total	
expenditures	 for	 monitoring,	 treatment,	 diagnostic	 tests,	 medication,	 etc.	 which	
result	from	the	treatment)	






























advantages	 and	 disadvantages.	 The	 ranking	 of	 such	 sources	 reflects,	 in	 part,	 the	
reliability	of	the	data	collected,	and	therefore	the	quality	of	the	analysis	results.	
The	 best-known	 source	 is	 the	clinical	 trial,	which	 belongs	 to	 a	wider	 class	 of	
studies	 called	 “controlled	 experiments”.	 Clinical	 trials	 are	 scientific	 experiments	with	
people	who	suffer	from	a	disease,	that	assess	the	difference	in	response	between	a	new	
treatment	and	an	alternative.	The	second	source	of	data	is	meta-analysis.	Meta-analysis	
is	 a	 statistical	 technique	 aimed	 at	 summarizing	 results	 obtained	 from	 clinical	 trials	
(Petiti,	1994).	It	constitutes	original	research	and	draws	its	information	from	the	clinical	
trials	 included	 in	 the	 analysis.	 Databases	 are	 repositories	 of	 data	 and	 records	
accumulated	 in	 the	 daily	 operations	 of	 large	 organizations.	 Depending	 on	 the	
































be	 understood,	 but	 they	 should	 also	 be	 sufficiently	 complex	 so	 that	 they	 incorporate	


































very	 robustly	 established	 for	 our	model	 to	 have	 any	 validity.	 Sensitivity	 analysis	 is	 a	
technique	which	 estimates	 the	 effect	 that	 different	 values	 of	 an	 independent	 variable	
have	on	 the	end	results	 (Jain	et	al.	2011).	Sensitivity	analysis	 is	very	 important	when	
examining	the	robustness	and	validity	of	our	conclusions	based	on	the	significance	of	the	
initial	parameters	(Meltzer,	2001;	Yoder,	2008).	It	needs	to	be	performed	mostly	when	

















to	medications	 as	 a	 result	 of	 environmental	 and	 individual	 factors	 including	 genomic	
variation.	Adverse	Drug	Reactions	(ADRs)	are	a	major	contributor	to	morbidity,	mortality	
and	costs	of	care	 [Classen	1997;	Classen	2010].	Considerable	effort	has	been	made	 to	






matched	with	activities	 to	measure	 the	effectiveness	and	 the	value	of	 genome-guided	
treatment	interventions.	
In	 recent	 years,	 there	 is	 a	 growing	 demand	 to	 measure	 the	 value	 of	
pharmacogenetics	 testing	 so	 that	 policymakers	 are	 well-informed	 to	 decide	 about	
adopting	and	reimbursing	pharmacogenetics	testing.	Presently,	economic	evaluation	in	
genomic	medicine	 and	pharmacogenetics	 is	 still	 in	 its	 infancy.	There	 are	 very	 limited	
economic	evaluation	studies	of	genome-guided	treatment	modalities	that	would	allow	















A	 study	 by	 Schackman	 and	 coworkers	 [2008]	 used	 a	 simulated	model	 of	 HIV	
disease	based	on	the	Prospective	Randomized	Evaluation	of	DNA	Screening	in	a	Clinical	









The	 authors	 concluded	 that	 the	 genetic	 testing	 strategy	 was	 preferred	 and	
resulted	 in	 a	 cost-effectiveness	 ratio	of	 $36,700/QALY	compared	with	no	 testing	 (the	
tenofovir	strategy	was	found	to	increase	cost	with	no	improvement	in	outcomes	thus	was	
dominated).	The	authors	stressed	that	the	model	was	robust	provided	that	abacavir	and	
tenofovir	 had	 equivalent	 efficacy	 and	 abacavir	 therapy	 was	 less	 expensive.	 This	
demonstrates	 that	 the	 result	 of	 an	 analysis	 is	 sensitive	 to	 changing	 conditions	 in	 the	
health	care	system	thus	may	not	remain	‘true’	in	the	face	of	these	changing	conditions.	
From	the	above,	 it	becomes	evident	 that	 there	 is	a	need	 to	evaluate	additional	
pharmacogenomic	studies,	based	on	different	types	of	economic	evaluation.	These	efforts	
will	 aim	 to	 demonstrate	 that	 pharmacogenomic	 testing	 is	 ready	 for	 clinical	
implementation,	based	on	the	continuously	increased	evidence	for	their	clinical	utility	































































































































































































































































































































































































































































































































































In	 the	 post-genomic	 era,	 in	 many	 European	 countries,	 very	 little	 is	 known	
regarding	 the	 level	 of	 awareness	 of	 healthcare	 professionals	 with	 respect	 to	
pharmacogenomics	and	personalized	medicine.	Here,	we	report	the	findings	of	an	in-
depth	 study	 in	 a	 single	 country,	 involving	 86	 pharmacists	 and	 208	 physicians,	 to	
assess	their	level	of	awareness	of	pharmacogenomics	and	personalized	medicine.	Our	
findings	indicate	that	around	60%	of	pharmacists	consider	their	level	of	knowledge	of	
personalized	 medicine	 to	 be	 very	 low,	 while	 over	 half	 of	 the	 pharmacists	 and	
physicians	 indicate	 that	 they	 would	 be	 unable	 to	 explain	 the	 results	 of	






















the	 context	 of	 rationalizing	 drug	 prescription	 but	 also	 by	 influencing	 the	 overall	
medical	decision-making	process	to	the	benefit	of	both	the	patient	and	the	national	
healthcare	system.	Analysis	of	an	individual’s	or	a	family’s	whole	genomic	sequence			





As	 a	 consequence,	 not	 only	 can	 preventive	 medicine	 strategies	 be	 optimized	 but	
conventional	 therapeutic	 interventions	 can	 also	 be	 individualized.	 The	 latter	
constitutes	 a	major	 challenge	 for	 customizing	 patient	 care	 (Ginsburg	 and	Willard,	
2009).		
Unfortunately,	 the	 level	 of	 public	 awareness	 of	 genomics	 and	 its	 impact	 upon	
society	is	often	rather	low,	and	the	same	is	true	for	the	healthcare	professionals	who	
have	been	entrusted	to	be	in	the	front-line	of	delivering	these	services	to	the	general	
public.	 The	 lack	 of	 genetics/genomics	 awareness	 among	 healthcare	 professionals	
constitutes	 a	major	barrier	 to	 expediting	 the	 implementation	of	 genomic	medicine	
with	its	potential	to	adjust	conventional	treatment	modalities	according	to	a	patient’s	
genomic	 profile.	 Health	 care	 providers,	 including	 physicians	 and	 pharmacists,	will	
play	 important	 roles	 in	 implementing	 pharmacogenomics	 in	 everyday	 practice.	
Education	 and	 training	 for	 these	 and	 other	 healthcare	 professionals	 regarding	
pharmacogenomics	 will	 help	 to	 ensure	 that	 pharmacogenomics	 technologies	 are	
appropriately	and	effectively	used	(Phillips	and	van	Bebber,	2004),	while	it	will	enable	
healthcare	professionals	to	interpret	and	apply	pharmacogenomic	information.	This	
situation	 is	exacerbated	by	a	poorly	developed	and	 inadequately	 regulated	genetic	
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testing	 landscape	 in	many	 European	 countries,	 as	 indicated	 by	 the	 paucity	 of	 the	
literature	on	this	topic	both	in	European	countries	(Hietala	et	al.,	1995;	Balck	et	al.,	
2009;	 Makeena	 et	 al.,	 2010)	 and	 the	 United	 States	 of	 America	
(http://oba.od.nih.gov/SACGHS/sacghs_home.html).	 Thus,	 determining	 the	 level	 of	
awareness	of	the	general	public	and	healthcare	professionals	with	respect	to	genomic	
medicine	and	its	potential	benefits	to	society,	together	with	the	challenges	and	pitfalls	
that	 need	 to	 be	 overcome,	 has	 become	 a	 major	 goal.	 For	 this	 reason,	 we	 have	
conducted	 nationwide	 surveys	 in	 Greece	 to	 critically	 ascertain	 patients’	 and	
healthcare	professionals’	views	about	pharmacogenomics	and	personalized	medicine.	
We	 have	 previously	 reported	 our	 results	 from	 several	 nationwide	 surveys	 to	
ascertain	the	landscape	of	the	private	genetic	testing	laboratories	in	Greece	(Mai	et	al.,	
2011).	We	have	also	performed	pilot	surveys	of	the	views	of	the	general	public	and	





genomics,	 personalized	medicine	 and	 their	 impact	 on	 society.	 This	 study	 provides	
novel	 insights	which	we	 hope	will	 be	 useful	 to	 other	 European	 countries	 that	 are	










(see	 Appendix	 2)	 from	 which	 the	 data	 on	 individual	 views	 of	 genetics,	
pharmacogenomics	 and	 personalized	 medicine	 were	 derived.	 Where	 necessary,	
clarifications	to	questions	posed	by	the	survey	respondents	were	provided,	both	to	









third	 section	 (questions	 8-15)	 aimed	 to	 assess	 the	 genomics	 knowledge	 of	 the	
respondents,	 and	 (d)	 the	 fourth	 section	 (questions	 16-35)	 posed	 20	 questions	 on	
various	 aspects	 of	 genetics,	 such	 as	 awareness	 of	 and	 personal	 opinions	 about	





all	 geographical	 regions	within	Greece.	This	 questionnaire	 contained	 the	 following	


























comprised	 the	 demographic	 characteristics	 of	 respondents,	 specifically	 their	 age,	




All	 statistical	 analyses	were	performed	using	 the	 Statistical	 Package	 for	 the	
Social	Sciences,	version	18.0	(SPSS	Inc.,	Chicago,	IL,	USA)	and	the	chi-square	test.	We	










The	 overall	 sample	 sizes	 and	 characteristics	 of	 the	 surveyed	 pharmacist	 and	
physician	groups	are	shown	in	Table	3.2.	Every	effort	was	made	in	the	context	of	both	






















survey	 were	 pathologists	 (50%),	 general	 practitioners	 (28%),	 surgeons	 (28%),	


























(b)	 involvement	 with	 genomics,	 genetic	 testing	 and	 pharmacogenomics,	 and	 (c)	
professional	 opinions	 regarding	 ethical,	 legal,	 societal	 and	 regulatory	 issues	










of	 genetics,	 pharmacogenomics	 and	 personalized	medicine	 was	 high	 or	 very	 high	
(Figs.	3.1A,	B).	Almost	half	 (45%)	of	physicians	volunteered	 that	 their	 knowledge	
level	of	pharmacogenomics	and	personalized	medicine	(Q12A)	was	poor	or	very	poor,	
while	 around	 1/4	 (24%)	 of	 respondents	 felt	 that	 their	 knowledge	 level	 of	
pharmacogenomics	and	personalized	medicine	was	high	or	very	high	(Fig.	3.1C).	A	















Finally,	 approximately	 3/4	 (78%)	 of	 the	 physicians	 and	 3/5	 (58%)	 of	
pharmacists	stated	that	they	would	be	interested	in	attending	educational	events	in	





number	 of	 genetic	 tests	 that	 are	 being	 made	 available	 from	 genetic	 laboratories	










were	aware	that	certain	drug	 labels	specify	 that	 it	 is	recommended	to	undertake	a	
pharmacogenomic	 test	 prior	 to	 obtaining	 the	 drug	 in	 question	 so	 as	 to	 avoid	 an	
adverse	drug	reaction	(Q26B;	Fig.	3.2A).	
It	is	broadly	accepted	that	pharmacogenomics	contributes	towards	a	reduction	
not	 only	 in	 healthcare	 costs	 by	minimizing	 adverse	drug	 reactions,	 but	 also	 in	 the	
overall	cost	of	developing	new	drugs	by	stratifying	patient	subgroups	in	clinical	trials.	
Therefore,	we	posed	 these	questions	 to	pharmacists	 in	order	 to	ascertain	whether	
they	 are	 familiar	 with	 these	 issues.	 We	 found	 that	 around	 3/5	 (60%)	 of	 the	
respondents	 believed	 that	 pharmacogenomics	 can	 help	 to	 reduce	 the	 occurrence,	
overall	 frequency	and	severity	of	adverse	drug	reactions	(Q31B),	while	almost	2/3	






























that	 they	 had	 advised	 their	 clients	 to	 undergo	 genetic	 and/or	 pharmacogenomic	




could	 not	 provide	 sufficient	 information	 to	 their	 clients	 or	 explain	 the	 results	 of	
pharmacogenomic	 tests	 to	 them	 (Q27B);	 this	 proportion	 was	 much	 lower	 in	 the	
physicians	group	(58%;	Q16A:	Fig.	3.3C).	
	
3.4.3.	 Professional	 opinions	 on	 ethical,	 legal,	 societal	 and	 regulatory	 issues	
pertaining	to	genetics	and	pharmacogenomics	




pharmacists)	 believe	 that	 in	 Greece	 there	 is	 currently	 neither	 a	 well-regulated	
environment	 nor	 the	 appropriate	 legal	 framework	 covering	 genetic	 and	
pharmacogenomic	testing	to	protect	the	general	public	and	ensure	privacy,	informed	
consent,	 control	 of	 the	 costs	of	 genetic	 analysis,	monitoring	of	 the	 accreditation	of	
genetic	laboratories,	etc;	Fig.	3.4A).	In	particular,	72%	of	the	pharmacists	thought	that	
there	was	the	potential	 for	pharmacogenomic	 information	to	be	 inappropriately	or	

















2/3	 of	 physicians	 and	 pharmacists	 (62%	 and	 66%	 respectively)	 believed	 that	 the	
pharmacogenomic	 testing	 costs	 should	 be	 covered	 by	 insurance	 companies	 (Fig.	
3.4C).	Overall,	the	majority	of	healthcare	professionals	(50%	of	physicians	and	70%	































opined	 that	 DNA	 changes	 could	 result	 in	 adverse	 drug	 reactions	 as	 compared	 to	
almost	2/3	(62%)	of	the	older	pharmacists	(Q14B;	p<0.001).	Further,	71%	of	younger	
pharmacists	were	of	the	opinion	that	pharmacogenomic	analysis	is	not	appropriate	
for	 all	 drugs,	 although	 this	 proportion	 was	 lower	 for	 older	 pharmacists	 (Q15B;	
p=0.042).	When	we	assessed	the	influence	of	post-graduate	education	on	genomics	








advent	 of	 high-throughput	 genotyping	 and	whole-genome	 sequencing	 analysis	 has	







awareness	 of	 healthcare	 professionals	 in	 relation	 to	 genomics	 and	 personalized	
medicine	so	that	the	delivery	of	genomic	services	may	be	expedited	in	their	respective	
healthcare	 systems.	 Genetics	 education	 and	 communication	 will	 also	 play	 an	
important	role	in	increasing	the	level	of	awareness	of	the	general	public	with	respect	








There	 are	 currently	 only	 a	 handful	 of	 studies	 in	 the	 literature	 that	 have	
attempted	 to	 quantify	 the	 differences	 between	 individual	 countries	 regarding	 the	








(mai	 et	 al.,	 2011;	 Pavlidis	 et	 al.,	 2012)	 and	 to	 correlate	 this	 information	with	 the	
private	genetic	testing	laboratories	in	Greece	(Sagia	et	al.,	2011).	Interestingly,	for	the	
first	 time	 in	 Europe,	 these	 surveys	 paid	 special	 attention	 to	 attitudes	 to	
pharmacogenomic	testing.		
This	 study	 has	 attempted	 to	 shed	 new	 light	 into	 the	 views	 of	 healthcare	
professionals	with	respect	to	genomic	medicine	and	pharmacogenomics	in	particular.	





genomic	 knowledge	with	 professional	 and	 training	 experience,	 and	 (d)	 this	 study	
highlighted	 the	 willingness	 of	 both	 target	 groups	 to	 participate	 in	 continuous	
educational	events	in	relation	to	pharmacogenomics.	
As	 with	 our	 previous	 study,	 we	 opted	 to	 carry	 out	 face-to-face	 interviews	
rather	than	acquire	information	by	means	of	impersonal	electronic	surveys	since	it	
allowed	 us	 to	 provide	 clarification	 to	 the	 respondents	 when	 required	 to	 do	 so.	







Integration	 of	 genomic	 information	 into	 the	 daily	 medical	 decision-making	
process	depends	upon	several	parameters.	Increased	awareness	of	various	aspects	of	
genomic	 medicine	 greatly	 facilitates	 the	 entire	 process.	 Our	 results	 indicate	 that	
approximately	60%	of	the	pharmacists	who	responded	to	our	survey	considered	their	
level	of	genetics	knowledge	to	be	low,	a	proportion	comparable	to	the	pharmacists	










as	well	 as	 a	 similar	 survey	 in	 the	 United	 States	 (McCullough	 et	 al.,	 2011),	 further	
outlining	the	need	for	expanding	pharmacogenomics	education	in	higher	education	
(Higgs	et	al.,	2008;	Lee	et	al.,	2012).		
This	 difference	 can	 most	 easily	 be	 explained	 by	 the	 fact	 that	 genetics	 and	
molecular	 biology	 courses	 are	 included	 for	 a	 longer	 period	 of	 time	 in	 the	medical	
schools	in	Greece	as	compared	to	the	schools	of	pharmacy.	It	is	unfortunate	that	in	the	
latter	 schools,	 the	 undergraduate	 curricula	 only	 address	 these	 topics	 quite	
superficially.	When	physicians	and	pharmacists	were	asked	to	self-assess	the	level	of	
their	 undergraduate	 education	 with	 respect	 to	 genetics	 and	 pharmacogenomics,	
similar	responses	were	given	(Fig.	3.1D).		
The	 educational	 level	 of	 the	 physicians	 and	 pharmacists	 with	 respect	 to	
genetics	 and	 pharmacogenomics	 could	 also	 be	 defined	 in	 relation	 to	 their	 level	 of	
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involvement	with	genetic	and	pharmacogenomic	testing	services.	Our	results	show	
that	 although	 physicians	 are	 more	 frequently	 involved	 with	 genetics	 and	
pharmacogenomics	in	their	routine	practice	as	compared	to	pharmacists,	more	than	
half	of	them	indicated	that	the	level	of	their	involvement	with	pharmacogenomics	was	
low	 (53%	 of	 physicians	 vs.	 73%	 of	 pharmacists).	 Moreover,	 significantly	 more	
physicians	 (53%)	 have	 advised	 their	 patients	 to	 undergo	 genetic	 and/or	
pharmacogenomic	testing,	compared	to	15%	of	pharmacists	(Fig.	3.3B).	To	this	end,	
we	should	also	bear	in	mind	that	physicians	may	recommend	more	genetic	testing	for	
genetic	 disorders	 as	 opposed	 to	 personalized	medicine	 and	 pharmacogenomics.	 A	
comparable	trend	was	also	observed	when	physicians	and	pharmacists	were	asked	
whether	 their	 patients	 had	 enquired	 about	 undertaking	 genetic	 and/or	









et	 al.,	 2013),	 but	 also	with	 similar	 surveys	 in	 the	United	 States	 (McCullough	 et	 al.,	
2011;	Stanek	et	al.,	2012;	Haga	et	al.,	2012).	As	previously	indicated,	the	proportion	of	
physicians	stating	that	they	were	unable	to	explain	genetic	and	pharmacogenomic	test	
results	was	much	 lower	 than	 the	pharmacists	while	 reciprocally	 the	proportion	of	
physicians	who	stated	that	they	were	in	a	position	to	adequately	interpret	genetic	test	
results	 was	 significantly	 higher	 than	 the	 pharmacists	 (58%	 and	 15%;	 p<0.01).	 A	
national	survey	by	American	Medical	Association	and	Medco	in	a	sample	of	10,303	
physicians,	 also	 showed	 that	 only	 10%	 believe	 they	 are	 adequately	 educated	 and	
trained	to	exploit	pharmacogenomic	tests	(Stanek	et	al.,	2012).	
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Although	 the	 results	 from	 the	 physicians’	 group	 were	 in	 full	 agreement	 with	 our	
previous	surveys	(Mai	et	al.,	2011;	Pavlidis	et	al.,	2012),	the	smaller	proportion	of	the	
pharmacists	 who	 were	 opposed	 to	 direct-to-consumer	 (DTC)	 genetic	 and	
pharmacogenomic	testing	is	of	special	interest,	warranting	further	investigation,	and	




need	 for	 a	 doctor	 to	 mediate	 between	 the	 patient	 and	 the	 diagnostics	 company	






It	 is	 broadly	 accepted	 that	 pharmacogenomics	 has	 the	 potential	 to	 improve	
quality	of	 life	at	the	same	time	as	reducing	healthcare	costs	by	minimizing	adverse	
drug	 reactions	 at	 both	 a	 personal	 and	 national	 level.	 Around	 2/3	 (60%)	 of	 the	
















and	 as	 such,	 they	 are	 expected	 to	 be	 able	 to	 use	 pharmacogenomic	 information	
appropriately	 in	 order	 to	 individualize	 treatment	 regimens.	 Pharmacists	 can	 be	
particularly	useful	in	the	implementation	of	pharmacogenomics,	mainly	by	assisting	
clinicians	 to	 ensure	 that	 all	 available	 pharmacogenomic	 information	 is	 taken	 into	
consideration	during	the	medical	decision-making	process,	or	by	acting	as	educators	
to	 patients	 and	 healthcare	 professionals	 in	 the	 context	 of	 raising	 awareness	 of	
pharmacogenomics.	 Pharmacists	 can	 play	 an	 important	 role	 in	 the	 application	 of	
pharmacogenomics	into	clinical	practice	to	improve	the	quality	and	safety	of	health	
care.	 However,	 the	 process	 for	 the	 application	 of	 pharmacogenomics	 data	 into	
pharmacy	 clinical	 practice	 must	 be	 defined	 and	 a	 viable	 business	 model	 in	 this	
emerging	field	must	be	developed	(American	Pharmacists	Association,	2011).	
As	 such,	 pharmacogenomics	 should	 play	 an	 integral	 role	 in	 modern	
undergraduate	curricula	in	schools	of	medicine	and	pharmacy.	Our	findings	suggest	
that	 younger	 pharmacists	 and	 those	 with	 graduate	 degrees,	 despite	 having	 less	
professional	 experience,	 are	 likely	 to	 have	 a	 better	 understanding	 of	 genetics	 and	
pharmacogenomics	(Fig.	3.5).	This	could	be	because	genetics	and	molecular	biology	
have	 only	 recently	 been	 added	 to	 the	 undergraduate	 pharmacy	 curriculum.	 These	
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findings	concur	with	 those	of	a	 recent	 survey	of	284	pharmacists	practicing	 in	 the	





	It	 should	be	noted	 that,	 in	our	own	study,	51	of	 the	pharmacists	who	were	
initially	 approached	 refused	 to	 participate	 in	 the	 survey	 (37%);	 14	 of	 these	were	
unaware	 of	 the	 term	 pharmacogenomics.	 It	 is	 also	 noteworthy	 that	 6	 of	 the	
pharmacists	 stated	 that	 this	 survey	 was	 insulting,	 maintaining	 that	 pharmacists	
should	not	participate	in	this	type	of	survey,	while	12	pharmacists	gave	other	excuses	
for	 not	 participating.	 Taken	 together,	 these	 findings	 indicate	 that	 although	 most	
pharmacists	have	a	positive	view	of	pharmacogenomics	and	are	willing	to	 increase	







of	 awareness	 of	 healthcare	 professionals,	 namely	 pharmacists	 and	 physicians	 on	
pharmacogenomics	 and	 personalized	medicine	 in	 Greece.	 Our	 results	 complement	
our	previous	 studies	 (Mai	 et	 al.,	 2011;	 Sagia	 et	 al.,	 2011;	Pavlidis	 et	 al.,	 2012)	 and	
provide	 new	 insights	 that	 should	 facilitate	 integration	 of	 pharmacogenomics	 into	
patient	care	in	Greece.	In	order	to	gain	further	insights	and	to	compare	the	level	of	
awareness	 of	 healthcare	 professionals	 over	 pharmacogenomics	 and	 personalized	


















































































































































































the	 poor	 understanding	 of	 the	 policies	 and	 key	 stakeholders	 involved	 in	 this	
translation	 process.	 We	 used	 the	 computerized	 version	 of	 the	 PolicyMaker	
political	mapping	 tool	 to	 collect	 and	organize	 important	 information	 about	 the	
pharmacogenomics	 and	 genomic	 medicine	 policy	 environment,	 serving	 as	 a	
database	for	assessments	of	the	policy’s	content,	the	major	players,	their	power	
and	 policy	 positions,	 their	 interests	 and	 networks	 and	 coalitions	 that	 connect	
them.	 Our	 findings	 indicate	 that	 the	 genomic	 medicine	 policy	 environment	 in	





















the	 national	 healthcare	 system,	 by	 means	 of	 exploiting	 an	 individual’s	 unique	
genomic	 profile.	 This	 enables	 healthcare	 professionals	 to	 make	 tailor-made	
disease	 and	 treatment	 risk	 assessments	 based	 on	 a	 patient’s	 unique	
pharmacogenomic	 profile	 (Guttmacher	 et	 al.,	 2010),	 hence	 individualizing	
conventional	therapeutic	interventions	(Cooper	et	al.,	2010).		
The	 Genomic	Medicine	 environment	 is	 complex,	 with	 a	 plethora	 of	 key	
players	and	stakeholders	with	varying	levels	of	genetics	awareness	and	education.	
Previous	studies	have	attempted	to	shed	light	into	the	level	of	genetics	awareness	
of	 the	 general	 public	 and	 have	 investigated	 the	 genetics	 education	 level	 of	
healthcare	professionals,	as	well	as	their	views	on	ethical,	legal	and	social	issues	
(ELSI)	pertaining	to	genomics	towards	adopting	certain	policies	and	perform	the	
necessary	 steps	 that	 would	 facilitate	 integration	 of	 genomics	 into	 healthcare.	




barrier	 to	expediting	 the	 implementation	of	genomic	medicine.	 In	addition,	 the	
lack	 of	 proper	 mapping	 of	 the	 opinions	 of	 various	 stakeholders	 leads	 to	 an	
inadequately	regulated	environment	in	the	field.		
We	have	previously	reported	the	results	from	several	nationwide	surveys	
to	 obtain	 the	 views	 of	 the	 general	 public	 and	 healthcare	 professionals	 (e.g.	
physicians,	pharmacists;	Mai	et	al.,	2011;	Mai	et	al.,	2014)	and	 to	ascertain	 the	
landscape	of	the	private	genetic	testing	laboratories	in	Greece	(Sagia	et	al.,	2011),	
with	 the	 aim	 of	 understanding	 the	 challenges	 and	 pitfalls	 in	 relation	 to	







pharmacogenomics	 and	 genomic	 medicine	 environment	 and	 to	 prioritize	 the	













organizations	 and	 the	 church,	 (e)	 consumers	 and	 citizens,	 (f)	 genetics	 and	
genomics	professional	associations,	(g)	the	Greek	Ministry	of	Health,	(h)	payers	
(including	both	the	public	health	insurance	fund	and	the	private	health	insurance	
industry),	 (i)	pharmaceutical	 and	biotechnology	 companies,	 (j)	pharmacies,	 (k)	
physicians	(Geneticists	and	other	medical	specialties),	(l)	the	Press	and	the	Media,	
(m)	 public	 and	 private	 providers,	 and	 (n)	 the	 Greek	 National	 Medicines	
Organization.		
All	 the	 above	 stakeholders	 were	 interviewed	 either	 by	 structured	




sector	 (governmental,	 non-governmental,	 political,	media,	 commercial,	 private,	




















aims	 to	 help	 policymakers	 managing	 the	 processes	 of	 reform	 and	 promote	
















Greek	bioethics	council	 BioethicsCouns	 Local	non-governmental	 Medium	support	 High	
Private	genetic	





Consumers	and	citizens	 Cons&Citiz	 Social	 Medium	support	 Medium	
Pharmaceutical	and	





Ministry	of	Health	 MoH	 Governmental	 Medium	opposition	 High	
Payers	(Private	Health	





Other	private	companies	a	 OthPrivComp	 Private	 High	support	 High	
Pharmacies	 Pharmacy	 Private	 High	support	 Medium	
Physicians	(Geneticists)	 Phys	(Genet)	 Private	 Medium	support	 Medium	
Physicians	(Others)	 Phys	(Others)	 Private	 Low	support	 High	
Press	and	Media	 (Press)	 Media	 Non-mobilized	 Medium	
Private	providers	 PrivProvider	 Private	 High	support	 Medium	
Public	providers	 PubProvider	 Governmental	 High	support	 Medium	
Greek	National	Medicines	













in	 Greece.	 Also,	 based	 on	 the	 same	 dataset,	 we	 have	 constructed	 a	 more	
comprehensive	 graphical	 presentation	 of	 the	 key	 stakeholders’	 initial	 position,	
including	their	various	interests	(deducted	from	Question	3	of	the	questionnaire;	
see	Appendix	2)	and	their	clustering	is	shown	in	the	Coalition	Map	(Fig.	4.3).			
Our	 data	 show	 that	 in	 general,	 half	 of	 the	 key	 stakeholders	 are	 highly	
supportive	of	pharmacogenomics	and	genomic	medicine	in	Greece,	among	which	
were	 pharmaceutical	 and	 biotechnology	 companies,	 as	 well	 as	 molecular	
diagnostics	laboratories.	These	also	have	strong	influence	and	are	driving	forces	
to	 support	 clinical	 implementation	 of	 pharmacogenomics	 from	 a	 technology-
driven	point	of	view.		
On	 the	 other	 hand,	 there	 is	 a	 medium	 opposition	 from	 the	 Ministry	 of	
Health	and	the	public	health	insurance	funds,	based	on	not	yet	fully	proven	cost	
effectiveness	of	a	pharmacogenomics	approach,	both	of	which	have	high	power	to	
intervene	 against	 the	 implementation	 of	 pharmacogenomics	 and	 genomic	
medicine	into	mainstream	clinical	practice.			
















contracted	by	20%	 in	4	years,	unemployment	 rate	 increased	by	15	percentage	
points	to	almost	24%	(European	Commission,	2013)	and	for	a	healthcare	system	










explain	 the	 medium	 opposition	 of	 these	 stakeholders.	 This,	 notwithstanding,	
contradicts	 the	 positions	 of	 both	 the	 National	 Medicines	 Organization	 (non-
mobilized)	 and	 the	National	 Bioethics	 Council	 (highly	 supportive),	 particularly	









































health	 insurance	 funds,	 a	 fact	 that	warrants	 further	 investigation	 and	 possibly	
exploitation	 in	 order	 to	 convince	 the	 latter	 funds	 to	 also	 adopt	 a	 supportive	




















































We	 found	 that	 citizens,	 geneticists,	 other	 physicians	 as	 well	 as	 the	







The	Media	 and	 the	 Press	 currently	 hold	 a	 neutral	 position	 on	 genomic	
medicine,	which	 if	 changed	 to	a	medium	to	high	support	and	present	objective	
opinions	and	facts	by	academics,	qualified	professionals,	and	regulatory	bodies,	it	





current	 position	 and	 power	 of	 the	 key	 stakeholders	 to	 intervene.	 These	
opportunities	and	obstacles	are	outlined	in	Table	4.3,	underlining	the	fact	that	the	
majority	 of	 the	 stakeholders	 seem	 to	 unveil	 their	 financial	 interest	 at	 a	 high	










environment	 and	 identifying	 the	 role,	 the	 interests	 and	 the	position	of	 the	 key	
stakeholders	 related	 to	 pharmacogenomics	 and	 personalized	 medicine.	 Our	
findings	underline	that	the	majority	of	the	key	stakeholders	are	favorably	viewing	
the	 implementation	 of	 genomic	medicine,	 despite	 the	 fact	 that	 the	Ministry	 of	
Health	and	the	public	health	 insurance	 funds	stand	at	 this	moment	against	 this	
new	trend	in	medical	practice.	It	is	anticipated	that	once	some	tangible	benefits	






steps	 and	measures	 not	 only	 to	maintain	 the	 overall	 positive	 attitude	 of	most	
stakeholders	 towards	 genomic	 medicine	 but	 most	 importantly	 to	 shift	 the	
remaining	 stakeholders	 from	 a	 neutral-to-negative	 opinion	 into	 a	 more	
supportive	position.	
Our	future	goal	is	to	replicate	this	study	not	only	in	Greece	in	the	coming	


































































































































Economic	 evaluation	 in	 genomic	 medicine	 is	 an	 emerging	 discipline	 to	
assess	the	cost-effectiveness	of	genome-guided	treatment.	Here,	we	developed	a	
pharmaco-economic	model	to	assess	whether	pharmacogenomic-guided	warfarin	
treatment	 of	 elderly	 patients	 with	 atrial	 fibrillation	 in	 Croatia	 is	 cost-effective	
compated	with	 non-pharmacogenomic	 therapy.	 The	 time	horizon	 of	 the	model	
was	set	at	one	year.	Our	primary	analysis	indicates	that	97.07%	(95%CI:	94.08%-
99.34%)	of	patients	belonging	to	the	pharmacogenomics-guided	group	have	not	
any	 major	 complications,	 compared	 to	 the	 control	 group	 (89.12%;	 95%CI:	
84.00%-93.87%,	 p<0.05).	 The	 total	 cost	 per	 patient	 was	 estimated	 at	 €538.7	
(95%CI:	 €526.3-€551.2)	 for	 the	 pharmacogenomics-guided	 group	 vs	 €219.7	
(95%CI:	€137.9-€304.2)	 for	 the	 control	 group.	 In	 terms	of	QALYs	gained,	 total	
QALYs	was	estimated	at	0.954	(95%CI:	0.943-0.964)	and	0.944	(95%CI:	0.931-
0.956)	 for	 the	 pharmacogenomics-guided	 and	 the	 control	 groups,	 respectively.	
The	 true	 difference	 in	 QALYs	 was	 estimated	 at	 0.01	 (95%CI:	 0.005-0.015)	 in	
favour	 of	 the	 pharmacogenomics-guided	 group.	 The	 incremental	 cost-





















embolism,	heart	 failure	and	 left	ventricular	dysfunction,	which	 in	turn	result	 in	
reduced	quality	of	life	and	higher	death	rates	(Camm	et	al.	2010;	Kirchhof	et	al.,	
2007;	 Steward	 et	 al.,	 2002;	 Thrall	 et	 al.,	 2006;	 Korantzopoulos	 et	 al.,	 2012).	
Moreover,	 AF	 also	 generates	 significant	 health	 care	 services	 utilization	 and	
represents	a	great	economic	burden	for	the	modern	healthcare	systems	(Steward	
et	al.,	2001;	Friberg	et	al.,	2003;	Wattigney	et	al.,	2003;	Steward	et	al.,	2004;	Coyne	
et	al.,	 2006;	Bruggenjurgen	et	al.,	 2007;	Reynolds	et	al.,	 2007;	Ghatnekar	et	al.,	
2008;	Ringborg	et	al.,	2008;	McBride	et	al.,	2009;	Wolowacz	et	al.,	2011;	Karampli	
et	al.,	2012).	
The	 primary	 goal	 in	 the	 treatment	 of	 AF	 patients	 using	 anticoagulation	
therapy	 is	 to	 reduce	 symptoms	 and	 to	 prevent	 complications.	 International	
guidelines	issued	by	the	European	Society	of	Cardiology	(National	School	of	Public	
Health,	2012)	provide	guidance	on	how	to	manage	patients	based	on	their	risk	





Warfarin	 dose	 requirement	 depends	 on	 several	 demographic	 and	
nutritional	factors,	as	well	as	the	medical	history	of	the	patient,	while	it	also	has	a	
strong	 genetic	 component.	 In	 particular,	 CYP2C9	 and	 VKORC1	 genotypes	 have	
been	shown	 to	 relate	 to	warfarin	metabolism.	 In	particular,	 carriers	of	CYP2C9	
genomic	 variants	metabolize	 S-warfarin	more	 slowly	 than	patients	bearing	 the	
wild-type	 allele,	 leading	 to	 elevated	 international	 normalized	 ratios	 (INRs)	 at	
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common	 initial	 doses	 of	 warfarin	 (Gage	 and	 Lesko,	 2008),	 while	 carriers	 of	
VKORC1	genomic	variants	require	a	lower	warfarin	dose	as	well,	to	appropriately	
inhibit	coagulation.	Obviously,	variations	in	both	genomic	loci	induce	resistance	
to	 warfarin	 (Gage	 and	 Lesko,	 2008).	 CYP2C9	 and	 VKORC1	 pharmacogenomic	
testing	has	been	reported	to	have	50%-60%	accuracy	in	predicting	the	warfarin	
maintenance	doses,	which	can	potentially	decrease	the	incidence	of	bleeding,	as	a	
result	 to	 the	 elevated	 INRs.	 As	 such,	 genotyping	 of	 pharmacogenomic	 variants	
related	to	warfarin	metabolism	has	the	potential	to	improve	clinical	management	
of	warfarin	treatment	and,	reciprocally	decrease	the	likelihood	of	bleeding.	In	this	
case,	 however,	 CYP2C9	 and	 VKORC1	 pharmacogenomic	 testing	 represents	 an	
additional	 cost	 item,	 which	 efficacy	 and	 economic	 outcomes	 still	 remains	
unknown	for	the	majority	of	healthcare	systems.	
In	Croatia,	like	in	many	developing	countries,	health	resources	are	scarce	
and	 demographic	 and	 technological	 trends	 are	 pushing	 budgets	 upwards.	
Therefore,	 it	 is	 important	 to	 find	 ways	 that	 can	 aid	 decision	makers	 to	 direct	
resources	 to	 the	 most	 efficient	 therapies.	 This	 is	 even	 more	 important	 in	 the	
context	 of	 the	 present	 global	 financial	 crisis	 and	 the	 pressures	 upon	 public	
budgets.	Hence,	to	guide	efficient	resource	allocation,	an	economic	evaluation	was	





The	 aim	 of	 the	 present	 study	 was	 to	 conduct	 an	 economic	 evaluation	








Healthcare	 system	 perspective;	 as	 such,	 only	 direct	 healthcare	 provider	 costs	
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reimbursed	by	 the	payers	were	 considered,	namely	 costs	which	are	associated	







All	 patients	 included	 in	 this	 study	with	 acute	 ischemic	 stroke	 (AIS)	 that	




newly	 discovered	 AF	 patients	 confirmed	 by	 HOLTER	 ECG;	 c)	 patients	 with	




for	 women;	 d)	 hepatic	 and	 renal	 insufficiency;	 and	 e)	 age<18	 year.	 Eligible	
patients	were	centrally	registered	and	stratified	according	to	sex,	age,	and	then,	






(genotype-guided	dosing	 group,	 PGx)	 or	 to	 the	 control	 group	 (standard	dosing	
group,	N-PGx).	 In	both	groups,	patients	were	permitted	to	receive	symptomatic	
drugs	like	antihypertensives,	statins,	or	antiepileptics	as	needed.		


















All	 104	(100%)	 102	(100%)	 0.555	
Male	 45	(43.3%)	 40	(39.2%)	 	
Female	 59	(56.7%)	 62	(60.8%)	 	
Age	[mean		+	SD	(years)]	
All	 67.7+13.6	 69.6+12.2	 0.424	
Male	 66.5+12.0	 67.2+11.3	 0.919	
Female	 68.7+14.7	 71.1+12.6	 0.449	
Weight	[mean+	SD	(kg)]	
All	 75.2+10.5	 74.3+10.5	 0.515	
Male	 83.9+6.5	 83.2+7.0	 0.557	
Female	 68.6+7.7	 68.6+8.1	 0.911	
Reason	for	oral	anticoagulant	therapy	
Chronic	Atrial	Fibrilation	 24	(23.1%)	 21	(20.6%)	 0.666	





















All	 16	(15%)	 8	(7.8%)	 0.09	
Male	 6	(13.3%)	 4	(10.0%)	 0.634	








that,	 the	doses	were	adjusted	depending	on	 the	 INR	measurement.	The	control	
group	 (N-PGx)	 consisted	 of	 102	 patients	 with	 the	 same	 indication	 for	














as	 asymptomatic	 microhematuria,	 slight	 gingival	 or	 vaginal	 bleeding	 or	 small	
subcutaneous	hematoma.	More	extensive	bleeding	("Major	complications")	were	
classified	into	two	subgroups:	a)	bleedings	that	did	not	require	discontinuation	of	
therapy,	 such	 as	 mild	 hemorrhage	 into	 the	 infarct	 zone	 without	 worsening	 of	


















































































with	AF	 in	Croatia	 in	a	1-year	time	horizon.	Our	pharmacoeconomic	model	 is	a	
decision	 tree	constructed	 in	a	TreeAge	Pro	Suite	2013	 (TreeAge	Software,	 Inc.,	
Williamstown,	MA).	Our	model	was	populated	with	cost	data	from	Croatia	public	
tariff	 lists,	 in	 line	 with	 current	 treatment	 guidelines	 on	 patient	 management,	
outcomes	and	economic	consequences.	Differences	relate	only	to	the	cost	of	the	
resources	 ‘consumed’	 at	 each	 corresponding	 node	 of	 the	 model	 and	 the	
corresponding	transition	probabilities.		
	 The	transition	probabilities	for	the	first	6	months	of	the	model	were	based	






short,	 the	 structure	of	 the	model	 is	 identical	 for	both	arms	and	 the	differences	
relate	only	to	the	cost	of	the	resources	expensed	and	the	transition	and	outcome	
probabilities	in	different	nodes	of	the	model.	The	model	simulates	the	progression	
of	 patients	 from	 the	 moment	 they	 start	 therapy,	 to	 various	 states	 based	 on	

















intervals.	 In	particular,	based	on	 the	 initial	data	 set	of	 trial	 (including	cost	and	
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utility	 data),	 5000	 new	 data	 sets	with	 the	 same	 number	 of	 observations	were	




















€253.21),	 a	 non-significant	 difference	 of	 €-15.60	 (95%UI:	 €-92.69-€67.45)	 in	
favor	of	N-PGx	group.	The	main	item	driving	total	treatment	costs	was	the	cost	of	
pharmacogenomic	testing	in	the	PGx	group,	accounting	for	approximately	75%	of	


















B-Mean	 5.7	 10.4	 97.07%	
B-SD	 0.1	 0.2	 1.39%	
B-95%	LCI	 5.4	 10.0	 94.08%	
B-95%	UCI	 5.9	 10.7	 99.34%	
B-min	 5.2	 9.81	 90.79%	
B-max	 6.1	 10.9	 100.00%	
N-PGx	Group	
B-Mean	 7.1	 13.9	 89.12%	
B-SD	 0.2	 0.2	 2.53%	
B-95%	LCI	 6.8	 13.4	 84.00%	
B-95%	UCI	 7.4	 14.3	 93.87%	
B-min	 6.6	 12.8	 77.95%	
B-max	 7.8	 14.8	 96.71%	
N-PGx	vs	PGx	
B-Mean	 1.5	 3.5	 -7.95%	
B-SD	 0.2	 0.3	 2.70%	
B-95%	LCI	 1.1	 3.0	 -13.37%	
B-95%	UCI	 1.9	 4.1	 -2.77%	
B-min	 0.7	 2.9	 -18.56%	

































B-Mean	 28.07		 17.95		 1.40		 140.25	 187.68		
B-SD	 15.72		 0.14		 0.04		 -	 15.74		
B-95%	LCI	 2.51		 17.68	 1.32		 -	 162.10	
B-95%	UCI	 63.82		 18.23		 1.49		 -	 223.44	
B-min	 0.00		 17.46		 1.26		 -	 159.16		
B-max	 103.39		 18.51		 1.58		 -	 262.90		
N-PGx	Group	
B-Mean	 147.39		 23.16		 1.53		 -	 172.07		
B-SD	 39.04		 0.19		 0.02		 -	 39.03		
B-95%	LCI	 76.14		 22.79		 1.50		 -	 100.67	
B-95%	UCI	 228.50		 23.52		 1.56		 -	 253.21	
B-min	 24.76		 22.43		 1.46		 -	 49.32		
B-max	 310.47		 23.87		 1.59		 -	 335.47	
Cost	Differences	(N-PGx	vs	PGx)	
B-Mean	 119.32		 5.20		 0.12		 -140.25	 -15.60		
B-SD	 40.43		 0.25		 0.05		 -	 40.43		
B-95%	LCI	 41.95		 4.72		 0.03		 -	 -92.89		
B-95%	UCI	 202.69		 5.69		 0.21		 -	 67.45		
B-min	 -9.68		 4.32		 -0.08	 -	 -144.77	













PGx	 538.7	€	 0.954	 319.4	€	 0.01023	 31,225	€	






We	 have	 then	 plotted	 the	 cost-effectiveness	 acceptability	 curve	 to	










Understanding	 the	 relative	 benefits	 of	 alternative	 strategies	 for	 elderly	




this	 case,	 warfarin	 has	 been	 considered	 as	 an	 effective	 treatment	 for	 those	
suffering	 from	AF	 and	 their	 use	 represent	 a	 standard	 practice	 in	 conventional	
medicine.	The	results	of	 the	analysis	showed	also	that	 the	PGx-guided	warfarin	
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represents	 a	 prominent	 option	 for	 those	 suffering	 from	 AF	 in	 Croatia	 who	
developed	ischemic	stroke.	It	must	be	noted	that	the	related	literature	in	economic	
evaluation	of	pharmacogenomics	 is	 still	 limited.	However,	 some	data	 exist.	 For	
instance,	 in	 a	 recent	 economic	 evaluation	 the	 objectives	 were	 to	 evaluate	 the	
potential	clinical	and	economic	outcomes	of	genotype-guided	warfarin	therapy	in	
elderly	patients	newly	diagnosed	with	AF	and	to	identify	a	threshold	in	bleeding	

































genotype-guided	 dosing	 versus	 standard	 induction	 of	 warfarin	 therapy	 for	










that	 genotype-guided	 dosing	 for	warfarin	 therapy	 does	 not	 appear	 to	 be	 cost-
effective,	with	the	potential	ICER	per	QALY	being	greater	than	$50,000.	Finally,	a	
recent	 study	 by	 You	 and	 coworkers	 (2014)	 showed	 that	 pharmacogenomics-




between	 PGx	 vs	 N-PGx	 is	 relatively	 small	 and	 someone	 could	 argue,	 from	 a	
statistical	point	of	view,	that	there	is	not	any	meaningful	difference.	Nonetheless,	
in	health	economics	the	rules	of	classical	statistical	inference	are	inconsistent	with	
the	 objectives	 of	 any	 coherent	 health	 care	 system	 and	 impose	 unnecessary	
opportunity	 costs.	 In	 case	 the	objective	 is	 to	maximize	health	gains	 for	a	given	
budget,	programmes	should	be	selected	based	on	the	posterior	mean	irrespective	
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of	 whether	 any	 differences	 are	 regarded	 as	 statistically	 significant.	 Therefore,	
analysts	 should	 focus	 their	 attention	 on	 estimation	 of	 cost-effectiveness	 rather	
than	on	hypothesis	testing	of	cost	or	effect	differences	(Briggs	and	O’Brien,	2001).	
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for	 which	 all	 major	 regulatory	 agencies	 recommend	 genetic	 testing	 to	 be	
performed	 to	 identify	 a	 patient’s	CYP2C19	 genotype	 in	 order	 to	 determine	 the	
optimal	antiplatelet	therapeutic	scheme.	The	CYP2C19*2	and	CYP2C19*3	variants	
are	loss-of-fucntion	alleles,	leading	to	abolished	CYP2C19	function	and	thus	have	
the	 risk	of	 thrombotic	 events	 for	 carriers	of	 these	 alleles	on	 standard	dosages,	
while	the	CYP2C19*17	allele	result	in	CYP2C19	hyperactivity.	Here,	we	report	our	






to	 11.2%	 of	 the	CYP2C19*1/*2	 and	CYP2C19*2/*2	 patients.	 There	were	 subtle	
differences	 between	 the	 two	 patient	 groups,	 as	 far	 as	 the	 duration	 of	
hospitalization	 and	 rehabilitation	 is	 concerned,	 in	 favor	 of	 the	 CYP2C19*1/*1	
group.	 The	mean	 cost	 for	 the	CYP2C19*1/*1	 patients	was	 estimated	 at	 €2,547	
versus	 €2,799	 in	 the	CYP2C19*1/*2	 and	CYP2C19*2/*2	 patients.	 Furthermore,	
based	 on	 the	 overall	 CYP2C19*1/*2	 genotype	 frequencies	 in	 the	 Serbian	
population,	a	break-even	point	analysis	indicated	that	performing	the	genetic	test	
prior	to	drug	prescription	represents	a	cost-saving	option,	saving	€13	per	person	
on	 average.	 Overall,	 our	 data	 demonstrate	 that	 pharmacogenomics-guided	
clopidogrel	treatment	may	represent	a	cost-saving	approach	for	the	management	






















Genomic	 variants	 in	 the	 CYP2C19	 gene	 have	 been	 shown	 to	 affect	
clopidogrel’s	activation,	which	directly	 impacts	on	 the	efficacy	of	 the	drug.	The	
loss-of-function	 variants	 CYP2C19*2,	 and	 CYP2C19*3	 abolish	 CYP2C19	 activity,	
rendering	 the	 patients	 intermediate	 or	 poor	 metabolizers	 in	 which	 case	
clopidogrel	is	insufficiently	activated	and	results	in	reduced	efficacy	(Scott	et	al.,	
2013).	In	the	latter	case,	an	alternative	therapeutic	agent	is	then	recommended,	
such	 as	 prasugrel	 or	 ticagrelor	 (Sibbing	 et	 al.,	 2010])	 On	 the	 other	 hand,	 the	






these	 variants	 are	 present	 in	 varying	 frequencies	mostly	 in	 Asians	 but	 also	 in	
Caucasians	and	African	Americans	(Mizzi	et	al.,	2016).	
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Contrary	 to	 the	 United	 States	 and	 European	 developed	 countries,	 in	
developing	countries,	there	is	often	a	scarcity	in	health	resources.	As	such,	policy	
makers	must	seek	alternative	strategies	to	make	the	optimal	use	of	the	resources	
available.	 In	 this	 case,	 economic	 evaluation	 plays	 an	 important	 role	 to	 assist	
decision	makers	 to	select	 the	most	optimal	 treatment	modalities	 (Snyder	et	al.,	












Overall,	 1,059	 consecutive	 ST	 Segment	 Elevation	 Myocardial	 Infarction	
(STEMI)	patients	were	admitted	 for	primary	PCI	between	 June	2010	and	April	
2011	at	the	Department	of	Cardiology	Clinical	Centre	of	Serbia,	Belgrade.	Of	these,	
66	 patients	 experienced	 in-hospital	 bleeding	 and	 were	 included	 in	 the	 study	











myocardial	 infarction	 (MI)	 with	 ST	 depression	 of	 ≥	 1	 mm	 in	 ≥	 2	 contiguous	
anterior	leads	(van	de	Werf	et	al.,	2003).		
	 The	 Bleeding	 Academic	 Research	 Consortium	 (BARC)	 classification	was	
used	 from	 the	 detailed	 clinical	 data	 of	 patients	within	 hospital	 bleeding.	 All	 in	
hospital	 bleeding	 events	 were	 assessed	 using	 BARC	 and	 Thrombolysis	 in	
myocardial	 infarction	 (TIMI)	 criteria.	 Major	 adverse	 cardiovascular	 and	
cerebrovascular	 events	 (MACCE)	 were	 defined	 as	 a	 composite	 of	 death,	
reinfarction,	 target	 vessel	 revascularization	 for	 ischemia	 or	 stroke.	 Stent	








of	 100	 IU	 per	 kilogram	of	 body	weight	 or	 50-60	UI/kg,	 if	 glycoprotein	 IIb/IIIa	
inhibitor	 (GPI)	 is	given	(van	de	Werf	et	al.,	2008).	Aspirin	(300	mg	orally)	was	











the	 TIMI	 criteria	 (combined	 TIMI	 major	 and	 minor	 bleedings).	 The	 primary	
clinical	efficacy	endpoint	was	the	cumulative	incidence	of	definite	and	probable	
stent	thrombosis	(ST)	during	a	follow	up	period.	The	primary	ischemic	endpoint	
was	 the	 composite	 of	 MACCE	 (death	 from	 any	 cause,	 nonfatal	 myocardial	
infarction,	 or	 stroke).	 Out	 of	 hospital	 clinical	 outcomes	 were	 obtained	 by	








the	 CYP2C19gene	 were	 amplified	 by	 polymerase	 chain	 reaction	 (PCR)	 and	
sequenced	using	the	Applied	Biosystems	3130	Genetic	Analyzer	using	the	BigDye	
Terminator	 v3.1	 Cycle	 Sequencing	 Kit	 (Applied	 Biosystems)	 to	 detect	 the	














constructed	 to	 compare	 two	 alternative	 treatment	 strategies	 for	 homozygous	
wild-type	 vs	 CYP2C19*2	 hetero-	 and	 homozygous	 patients	 that	 undergo	
clopidogrel	treatment.	The	life	horizon	of	the	model	was	considered	to	be	1	year.	
This	 pharmacoeconomic	 model	 is,	 in	 principle,	 a	 decision	 tree,	 which	 is	
subsequently	populated	with	cost	data	from	the	Serbian	public	tariff	lists.	Due	to	
lack	 of	 appropriate	 data,	 no	 efficacy	 data	 were	 taken	 into	 consideration.	 As	
illustrated	in	Figure	6.1,	in	accordance	with	strategy	“A”,	a	random	patient	will	be	














































































The	 nature	 of	 the	 present	 analysis	 requires	 undertaking	 of	 uncertainty	
analyses.	 The	 management	 of	 patients,	 the	 probabilities	 associated	 with	 the	
various	 outcomes	 are	 subject	 to	 variation	 and	 the	 same	 applies	 to	 patient	
treatment	costs.	The	data	used	also	come	from	different	sources	and	are	subject	
to	uncertainty,	which	 is	why	computer-simulated	clinical	and	economic	models	








particular,	 in	 every	 simulation,	 the	 value	 for	 each	 parameter	 is	 determined	
independently	and	at	random	from	the	prespecified	distributions,	and	the	results	
are	recalculated.		
The	 bootstrapping	 was	 run	 in	 total	 5000	 times	 and	 the	 results	 of	 the	
probabilistic	 analysis	 were	 used	 to	 calculate	 uncertainty	 intervals.	 It	 must	 be	
noted	that	this	technique	incorporates	the	probabilistic	nature	of	variables,	and	












to	 11.2%	 in	 the	 CYP2C19*1/*2	 and	 CYP2C19*2/*2	 patients	 arm.	 The	 average	
number	of	hospitalization	days	for	the	CYP2C19*1/*1	patients	was	estimated	at	
10.1+6.5	 days,	 compared	 to	 11.0+	 6.9	 days	 in	 the	 CYP2C19*1/*2	 and	
CYP2C19*2/*2	 patients	 arm.	 The	 mean	 stay	 in	 a	 rehabilitation	 center	 was	
estimated	 to	 be	 24.1+	 8.8	 and	 24.6+	 6.2,	 for	 the	 CYP2C19*1/*1	 versus	 the	








In	 short,	 the	mean	cost	 for	 the	CYP2C19*1/*1	patients	was	estimated	at	
€2,547	 (95%CI:	€2,217-€2,966)	 versus	€2,799	 (95%CI:	€2,251-€3,455)	 in	 the	
CYP2C19*1/*2	and	CYP2C19*2/*2	patients,	indicating	a	cost	difference	in	favor	of	
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the	 former	patient	group.	For	 the	CYP2C19*1/*1	patient	group,	 the	main	 factor	
contributing	 mainly	 to	 the	 total	 cost	 was	 the	 hospitalization	 costs	 (79.2%	 on	
average	of	the	total	cost),	followed	by	the	cost	of	rehabilitation	(11.2%),	the	cost	
of	vascular	operation	(4.2%),	 the	cost	of	RePCIs	 (2.6%)	and	 the	cost	of	genetic	
testing	(2.4%).	Similar	results	were	obtained	for	the	case	of	the	CYP2C19*1/*2	and	


























In	 accordance	 with	 the	 sample	 analysis,	 the	 percentage	 of	 the	
CYP2C19*1/*1	 patients	 in	 the	 total	 population	was	 estimated	 at	 71.1%	 versus	
28.9%	 in	 the	CYP2C19*1/*2	 and	CYP2C19*2/*2	 group.	 In	 the	 strategy	 analysis	
presented	 below,	 it	 is	 assumed	 that	 these	 percentages	 hold	 true	 and	 are	




based	 on	 changes	 in	 the	 percentage	 of	 the	 CYP2C19*1/*1	 patients	 in	 the	 total	
population	 (Fig.	 6.3).	 In	 the	 base-case	 analysis	 (CYP2C19*1/*1=71.1%),	 it	was	
estimated	 that	 strategy	 B	 (performance	 of	 the	 genetic	 test)	 represents	 a	 cost-
saving	option,	saving	€13	per	person	on	average,	compared	with	strategy	A.	As	
expected,	 strategy	 B	 becomes	 less	 attractive	 as	 the	 percentage	 of	 the	






















as	 contrary	 to	 our	previous	 study,	 since	 the	present	 analysis	 (1)	 is	 based	on	 a	
retrospective	study,	and	(2)	is	a	health	economics	rather	than	a	cost-effectiveness	
analysis.	
Clopidogrel	 represents	 a	 very	 well-studied	 example	 for	 economic	
evaluation,	based	on	clinical	 trials	and	meta-analyses.	Clopidogrel	 is	commonly	
used	in	 individuals	with	acute	coronary	syndrome	(ACS)	to	reduce	their	risk	of	
adverse	 cardiovascular	 (CV)	 outcomes.	 The	 introduction	 of	 new	 therapeutic	
alternatives	to	clopidogrel	raised	the	question	of	whether	a	genotype-guided	use	
of	 clopidogrel	 is	 more	 cost-effective	 compared	 to	 the	 universal	 use	 of	 newly	







were	 associated	 with	 improved	 efficacy.	 The	 Clinical	 Pharmacogenetics	
Implementation	 Consortium	 (CPIC)	 recommends	 these	 drugs	 as	 an	 alternate	












the	 universal	 classification	 of	 MI.	 The	 cost-effectiveness	 analysis	 included	 the	
costs	 of	 MI,	 urgent	 target	 vessel	 revascularization,	 stroke	 and	 major	 bleeding	
events.	One-way	and	probabilistic	sensitivity	analyses	were	performed,	indicating	
that	 clopidogrel	 therapy	 was	 the	 least	 costly	 and	 the	 least	 effective,	 when	
compared	 to	 the	 CYP2C19	 genotype-guided	 therapy	 with	 an	 incremental	 cost-
utility	ratio	of	USD	4,200.	Prasugrel	therapy	was	costlier	and	less	effective	than	
both	 other	 strategies.	 Sensitivity	 analyses	 again	 showed	 the	 importance	 of	 the	
relative	 risk	 of	 developing	 MI	 or	 stroke	 between	 homozygous	 normal	 and	
heterozygous	patients	for	a	LoF	CYP2C19	allele.	As	the	risk	of	developing	MI	or	
stroke	between	patients	with	and	without	the	CYP2C19	variant	allele	decreased,	
CYP2C19	genotype-guided	 therapy	became	 less	 attractive	 in	 comparison	 to	 the	
universal	 clopidogrel	 therapy.	 Similar	 results	 were	 also	 reported	 from	 others,	
where	the	CYP2C19	genotyping-treatment	arm	was	dominant	to	both	clopidogrel	
and	prasugrel	treatment	(Lala	et	al.	2013;	Reese	et	al.	2012).	
Interestingly,	 as	 far	 as	 the	 newly	 developed	 drugs	 are	 concerned,	 a	
randomized	 control	 study	 has	 shown	 a	 higher	 efficacy	 of	 ticagrelor	 treatment,	
compared	to	clopidogrel,	irrespectively	of	the	CYP2C19	genotype	(Wallentin	et	al.,	
2010).	 In	 particular,	 these	 authors	 suggested	 that	 the	 CYP2C19	 genetic	 testing	
prior	to	dual	antiplatelet	treatment	is	not	needed	in	the	case	of	universal	ticagrelor	
therapy.	The	end	point	of	this	study	was	the	composite	outcome	of	cardiovascular	
death,	 myocardial	 infarction	 and	 stroke	 and	 major	 bleeding	 events	 were	
considered	as	safety	outcomes.	Taking	these	probabilities	into	account	the	cost-
effective	 analysis	 was	 performed	 from	 the	 Australian	 health-care	 system	
prospective	(Sorich	et	al.,	2013).	Only	the	costs	of	the	primary	outcomes	without	
the	cost	of	bleeding	events	were	considered.	The	authors	compared	the	universal	
clopidogrel	 therapy,	 the	 universal	 ticagrelor	 therapy	 and	 the	 genotyping	 of	
CYP2C19	with	the	use	of	ticagrelor	in	individuals	with	a	LoF	allele	and	clopidogrel	
in	 individuals	 without	 a	 LoF	 allele.	 One-way	 deterministic	 and	 probabilistic	
sensitivity	 analyses	 were	 undertaken.	 It	 was	 concluded	 that	 the	 CYP2C19	
genotyping	 strategy	 was	 more	 expensive	 compared	 with	 the	 universal	 use	 of	
clopidogrel,	 but	 it	 provided	 greater	 effectiveness	 and	 the	 ICER	AUS$	 6000	 per	
QALY,	was	considered	to	be	cost-effective.	However,	the	most	effective	strategy	
 122	
was	 the	 universal	 use	 of	 ticagrelor,	 as	 the	 ICER	 was	 AUS$	 23,000	 per	 QALY	







when	 compared	 to	 the	 genotype-driven	 treatment	 at	 a	 cost	 below	 a	 typically	
accepted	threshold	(Crespin	et	al.,	2011).	Sensitivity	analysis	again	showed	that	
the	 hazard	 ratio	 of	 death	 for	 ticagrelor	 compared	 with	 clopidogrel	 sets	 the	
difference	on	which	strategy	is	the	most	cost-effective.	
Our	study	has	a	number	of	limitations.	First	of	all,	we	opted	to	model	the	
course	 of	 the	 disease	 in	 a	 simple	 manner	 based	 on	 data	 availability	 and	 any	
complexities	associated	with	clopidogrel	treatment	were	not	taken	into	account	
in	 the	 model	 design.	 Also,	 certain	 assumptions	 have	 been	 obtained	 from	 the	
literature,	as	they	were	not	available	by	the	raw	data.	Nevertheless,	we	feel	that	
these	assumptions	create	some	bias	but	for	both	arms	of	the	model	and	as	such	
we	do	not	 expect	 such	bias	 to	 cause	 alterations	 in	 the	 final	 conclusions	of	 this	
study.	 Another	 limitation	 of	 the	 study	 is	 the	 small	 number	 of	 patients.	
Furthermore,	the	results	of	this	model	have	to	be	strictly	considered	in	the	context	




health	 economic	 analysis,	 and	 not	 to	 perform	 a	 comprehensive	 budget	 impact	
















well	 to	 clopidogrel,	 particularly	 since	 these	 patients	 constitute	 the	 majority.	
Hence,	 the	 final	 goal	 of	 these	 considerations	 is	 to	 determine	 a	 balanced	 and	
rational	approach	to	the	treatment,	i.e.	substitution	of	clopidogrel	only	in	patients	
with	genetically	confirmed	presence	of	a	CY2C19	LoF	allele.	In	addition,	with	the	









Based	 on	 the	 current	 prices	 and	 resource	 utilization	 in	 Serbia,	 our	
retrospective	study	 indicates	 that	genotype-guided	clopidogrel	 treatment	could	
represent,	 under	 certain	 assumptions,	 a	 cost-saving	 treatment	 option	 for	
CYP2C19*1/*2	and	CYP2C19*2/*2	patients	suffering	from	myocardial	 infarction	
and	 support	 results	 from	 previous	 studies	 involving	CYP2C19	 LoF	 alleles.	 This	
study	is	one	of	the	very	few	economic	analyses	to	be	conducted	in	a	developing	
country	 clinical	 setting	 in	 Europe	 and	 Southeast	 Asia	 (Snyder	 et	 al.,	 2014;	


































































































































































































































































































Genomic	 Medicine	 aims	 to	 improve	 therapeutic	 interventions	 and	
diagnostics,	the	quality	of	life	of	patients,	but	also	to	rationalize	healthcare	costs.	
To	 reach	 this	 goal,	 careful	 assessment	 and	 identification	 of	 evidence	 gaps	 for	
public	health	genomics	priorities	are	required	so	that	a	more	efficient	healthcare	
environment	 is	 created.	 Here,	 we	 propose	 a	 public	 health	 genomics-driven	
approach	 to	 adjust	 the	 classical	 healthcare	 decision	 making	 process	 with	 an	
alternative	 methodological	 approach	 of	 cost-effectiveness	 analysis,	 which	 is	
particularly	helpful	 for	genomic	medicine	 interventions.	By	combining	classical	
cost-effectiveness	analysis	with	budget	constraints,	social	preferences	and	patient	
ethics,	 we	 demonstrate	 the	 application	 of	 this	 model,	 the	 Genome	 Economics	
Model	(GEM),	based	on	a	previously	reported	genome-guided	intervention	from	a	
developing	country	environment.	The	model	and	the	attendant	rationale	provide	
a	 practical	 guide	 by	which	 all	major	 healthcare	 stakeholders	 could	 ensure	 the	
sustainability	 of	 funding	 for	 genome-guided	 interventions,	 their	 adoption	 and	
coverage	by	health	insurance	funds,	and	prioritization	of	the	Genomic	Medicine	
research,	 development	 and	 innovation,	 given	 the	 restriction	 of	 budgets,	
particularly	 in	 developing	 countries	 and	 low-income	 healthcare	 settings	 in	
developed	countries.	We	conclude	with	a	discussion	of	the	implications	of	the	GEM	
















strategically	 identify	 and	 adequately	 target	 evidence	 gaps	 for	 public	 health	
genomics	priorities	 to	create	a	more	efficient	healthcare	environment.	 In	other	
words,	 evidence	 on	 the	 value	 of	 pharmacogenomics	 and	 Genomic	 Medicine	 is	
needed	 to	 persuade	 policymakers	 and	 clinicians	 for	 genome-guided	 decision	
making,	 related	 to	adoption	and	coverage	by	 insurance	 funds,	and	 to	prioritize	
research,	development	and	innovation	(Snyder	et	al.,	2014).		
Economic	evaluation	aims	 to	assess	whether	 the	 financial	 investment	 in	
specific	 health	 care	 interventions	 will	 provide	 “value	 for	 money”	 in	 achieving	
policy	 aims	 and	 also	 to	 inform	 decision	 makers,	 comparing	 the	 costs	 and	
therapeutic	 consequences	 of	 new	 and	 innovative	 with	 existing	 interventions	
already	used	by	the	healthcare	system.	So	far,	and	for	the	policy	makers	to	access	
the	 value	 of	 innovative	 interventions,	 the	 commonly	 used	 investigation	 is	
implemented	via	the	determination	of	incremental	cost	effectiveness	ratio	(ICER)	








amount	 a	 policymaker	 was	 willing	 to	 pay	 for	 an	 additional	 QALY,	 the	 new	
intervention	 is	 a	 “cost-effective	 option”	 and	 meets	 one	 of	 the	 criteria	 for	
reimbursement	 by	 the	 payers	 (McCabe	 et	 al.,	 2008)	 (Fig.	 7.1).	 It	 must	 be	
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highlighted	that	this	amount	of	money	is	not	fixed	(and	may	vary	within	a	specific	
range),	when	 taken	 into	 account	 other	 criteria	 for	 the	 reimbursement	process,	
such	 as	 the	 particular	 features	 of	 the	 condition,	 the	 availability	 and	 clinical	





country-specific	 context,	 taking	 also	 into	 account	 the	 age	 and	 the	 gender	 of	
beneficiaries,	their	deservedness,	and	other	ethical	issues.		
Because	 the	 above	 approach	 does	 not	 incorporate	 affordability	 when	
making	 judgments	 about	 cost	 effectiveness,	 an	 additionally	 separated	 budget	
impact	analysis	should	also	be	implemented	to	determine	the	economic	burden	of	
short	and	medium-term	effects	on	budgets	and	other	resources	to	reach	a	 final	
conclusion.	 Nonetheless,	 a	 “cost-effective”	 intervention,	 determined	 by	 the	
approach	described	above,	may	not	necessarily	be	affordable	from	an	economic	
point	 of	 view	 and	 the	 criteria	 for	 the	 final	 verdict	 of	 adoption	 or	 rejection,	
frequently,	 remains	unclear.	 In	 addition	 to	 that,	 other	 concerns	have	also	been	




and/or	 determined	 in	 a	 range)	 approach	might	 lead	 to	 controversial	 decisions	














technology	 is	 far	 less	 effective	 compared	 with	 the	 standard	 one,	 the	 classical	
model,	 at	 least	 in	 theory,	 assumes	 that	 “infinitively”	 less	 effective	 technologies	
could	 be	 adopted	 based	 only	 on	 cost	 criteria.	 Even	 in	 the	 case	 of	 developing	









boundaries	 described	 above,	 are	 not	 formally	 taken	 into	 consideration	 in	 the	
classical	 model.	 In	 addition	 to	 that,	 the	 classical	 theory	 assumes	 that	 the	
willingness-to-pay	 for	 a	 QALY	 is	 independent	 of	 the	 actual	 difference	 in	
effectiveness	between	different	health	technologies	even	within	the	same	disease-
specific	context.	In	that	sense,	economic	evaluation	does	not	differentiate	between	
a	 truly	 innovative	 health	 technology,	 a	 “me-too”	 health	 technology	 or	 even	 a	
generic	health	technology	and	reimburse	proportionally	equally	each	one	of	them.		





























the	 real	 therapeutic	benefit	 in	 a	patient’s	 life	 and	at	 the	 same	 time	 the	payer’s	



















(c)		 the	 maximum	 amount	 of	 money	 is	 willing	 to	 invest	 or	 save	 within	 two	
boundaries.	 Furthermore,	 the	 GEM	model,	 contrary	 to	 the	 classical	 model	
does	not	conduct	a	separate	cost-effectiveness	and	budget	impact	analysis,	in	
order	to	avoid	the	problem	of	technologies	which	are	“cost-effective”	but	not	













































intervention),	 and	 without	 any	 meaningful	 differentiation	 from	 existing	
interventions,	the	average	willingness	to	pay	for	a	QALY	is	expected	to	be	low	(Fig.	
7.3).	 For	 more	 innovative	 interventions	 with	 some	 difference	 in	 terms	 of	
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effectiveness,	(“small/fair”	interventions),	a	higher	average	willingness	to	pay	for	
a	 QALY	 (but	 also	 smaller	 than	 those	 offered	 by	 the	 classical	 model)	 can	 be	
expected,	 also	 in	 accordance	 to	 practical	 evidence	 (Kvamme	 et	 al.,	 2010).	 For	
innovative	interventions	with	significant	difference	in	terms	of	effectiveness,	the	
average	willingness	to	pay	for	every	unit	of	QALY	is	expected	to	be	very	high	in	
comparison	 with	 classical	 model.	 As	 the	 difference	 in	 effectiveness	 increases	
further	(breakthrough	technology),	we	meet	the	budget	constraints	criteria	and,	






made	 by	 policy	 makers	 or	 the	 literature	 (Fig.	 7.3).	 Finally,	 the	 new	 model	 is	
different	compared	with	the	classical	one,	 in	the	sense	that	 it	drives	healthcare	





To	 demonstrate	 the	 usefulness	 of	 the	 proposed	 new	 model	 in	
pharmacogenomics	and	Genomic	Medicine	interventions,	we	have	employed	GEM	
to	 a	 recently	 published	 real-file	 example	 of	 pharmacogenomic	 (PGx)-guided	
versus	 non-pharmacogenomic	 (N-PGx)-guided	 warfarin	 treatment	 of	 elderly	















guided	 warfarin	 treatment	 being	 cost-effective	 increases	 significantly	 at	 a	
willingness	to	pay	threshold	in	the	range	of	€40,000	to	€50,000	per	QALY,	used	in	











In	 particular,	 our	 findings	 indicated	 that	 the	 total	 cost	 per	 patient	 was	
estimated	at	€538.7	for	the	PGx-guided	group	vs	€219.7	for	the	control	group	and	
total	QALYs	was	estimated	at	0.954	and	0.944	for	the	PGx-guided	and	the	control	
groups,	 respectively	 (Mitropoulou	 et	 al.,	 2015).	 The	 incremental	 cost-
effectiveness	was	estimated	at	€31,225/QALY	(ΔC/ΔΕ=	€319.4/0.01023).	Based	























PGx	 in	 order	 to	 invest	 all	 the	 additional	 available	 amount	 of	 money.	 On	 the	





The	 present	 analysis	 of	 GEM	 indicates	 that	 the	 probability	 of	 a	 new	
technology	 being	 cost-effective	 is	 a	 function	 not	 only	 of	 a	 disease-specific	







As	medical	 research	 is	 one	 of	 the	 leading	 priorities	 in	 the	 society,	 it	 is	
essential	to	improve	the	lives	of	patients	and,	at	the	same	time,	the	economy	as	a	
whole.	On	the	other	hand,	medical	expenditure	is	expected	to	be	covered	by	the	
Insurance	 Funds	 and	 usually	 lead	 to	 an	 uncontrolled	 growth	 in	 health	 care	
expenditure.	In	view	of	the	limited	resources,	especially	in	developing	countries	
and	 low-resource	 environments	 (Snyder	 et	 al.,	 2014),	 economic	 evaluation	
provides	a	criterion	for	the	final	decision	concerning	the	adoption	of	certain	new	
and	 innovative	 technologies.	 The	 classical	 approaches	 have,	 notwithstanding,	
some	inconsistencies	and	drawbacks.		
In	this	paper,	we	propose	an	alternative	methodological	approach,	taking	











	In	 an	 attempt	 to	 practically	 describe	 the	 real-world	 situation,	 the	 GEM	
relaxes	the	“fixed”	and/or	disease-specific	assumption	of	willingness	to	pay	for	a	
QALY,	 allowing	 a	 flexible,	 upper	 bounded,	 budget.	 Furthermore,	 the	 model	
encourages	the	determination	of	willingness	to	pay	to	be	different	across	different	
treatment	 areas,	 taking	 into	 account	 the	 differences	 in	 “production”	 of	 a	QALY	
amongst	 patients’	 groups	 (e.g.	 cardiovascular	 patients,	 oncology	 patients	
etcetera),	 and	 even	 among	 the	 same	 patient	 groups	 but	 different	 healthcare	
systems.	 This	 argument	 of	 specific	 context	 and	 varying	 determination	 of	
willingness	 to	 pay	 is	 also	 in	 accordance	with	 related	 literature	 (Bridges	 et	 al.,	











the	 budget	 is	 exogenous	 and	 was	 set	 by	 the	 budget	 holders.	 Indeed,	 budget	
allocation	 lies	 on	 historical	 and	 political	 background	 in	 each	 country,	 and	 the	
optimal	reallocation	across	healthcare	sections	or	is	not	always	desirable,	when	
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sacrifices	 the	 transparency	 or	 consistency	 of	 decision	 making,	 the	 equality	 or	
other	ethical	issues	(Schwappach,	2002).	In	that	sense,	the	present	model	does	not	
address	the	question	of	how	to	allocate	available	healthcare	resources	to	different	
diseases	 based	 on	 a	 common	 measure	 for	 health.	 In	 order	 to	 do	 so,	 several	




disease	 context	 and	 for	 innovative	 interventions	 with	 greater	 effectiveness	
compared	with	 the	standard	ones,	when	considering	 the	 introduction	of	a	new	










de	 facto	 budget	 availability	 in	 a	 specific	 disease	 context.	 The	 aggregate	 sum	of	
costs	 and	 effectiveness	 across	 several	 disease	 areas	 does	 not	 necessarily	
represent	 the	overall	maximum,	as	 the	perceived	 importance	by	policy	makers	
and	 society	 for	 different	 QALYs	 have	 not	 been	 fully	 addressed	 and	 the	 budget	
cannot	 be	 fully	 reallocated	 automatically	 across	 different	 therapeutic	 areas.	
Nonetheless,	we	argue	that	the	“health	optimization	problem	given	a	fixed	budget”	
for	 the	 entire	 society,	 despite	 appealing	 as	 a	mathematical	 problem	 in	 theory,	
cannot	be	so	easily	addressed	in	a	real-world	setting.		
Uncertainty	 (Ramsey	 et	 al.,	 2005),	 lack	 of	 data	 or	 knowledge	 for	
preferences	(Weyler	and	Gandjour,	2011),	lack	of	training	of	policy	makers	(Veney	






of	 social	 preferences,	 requires	 not	 only	 a	 scientific	 approach	 to	 evaluate	 the	
opportunity	 cost	 between	 comparable	 treatments,	 but	 also	 the	 knowledge	 of	
societal	utility	function	and	the	knowledge	of	different	weights	for	different	QALYs	
as	mentioned	before	(Wailoo	et	al.,	2009).	If,	and	only	if,	the	above	prerequisites	
were	 satisfied,	 one	 could	 estimate	 the	 true	value	of	willingness	 to	pay	 and	 the	
desired	maximization	treatment	mix	across	several	disease-specific	areas.	Despite	
the	fact	that	mathematical	programming	could	incorporate,	in	a	quantitative	form,	









a)		 To	determine	 (based	on	prevalence,	 incidence,	market	penetration	and	 the	
available	total	budget	for	a	disease),	the	maximum	amount	of	money	which	
could	 be	 invested	 per	 patient	 in	 the	 future	 only	 in	 case	 of	 specific	
requirements,	in	terms	of	effectiveness,	are	met,	
b)		 To	determine	the	amount	of	greater-than-the-standard	effectiveness,	which	
differentiate	 amongst	 “me-too”,	 “fair”,	 “innovative”,	 “very	 innovative”	 and	
“breakthrough”	technologies,	






e)		 To	 determine	 in	 a	 quantitative	 manner	 the	 proportional	 rule	 for	
reimbursement	 across	 the	 above-mentioned	 technologies	 (even	 those	with	
greater	 or	 less	 effectiveness).	 For	 those	 technologies	 with	 greater	
effectiveness,	 the	 society	 is	willing	 to	 pay	 a	 percentage	 of	 the	 maximum	
amount	of	money	which	could	invest	at	most,	in	relation	with	the	percentage	
of	maximum	expected	effectiveness	attained	by	the	new	technology.	For	those	
technologies	 with	 less	 effectiveness,	 the	 society	 is	 willing	 to	 accept	 a	
percentage	 of	 less	 effectiveness	 compared	 with	 the	 least	 acceptable,	 in	





It	 must	 be	 highlighted	 that	 the	 actual	 issue	 of	 financial	 resource	
management,	in	practice,	is	primarily	a	political	issue	and	requires	a	knowledge	of	
the	politics	and	sociology	of	technology	and	innovation-in-society	(Sclove,	1989;	
Nowotny,	 2015).	 Unfortunately,	 quantitative	methods	 or	 logical	 approaches	 as	
those	 described	 above	 are	 not	 always	 adequate	 to	 resolve	 by	 themselves	 such	











In	 this	 context,	 we	 argue	 that	 decisions	 as	 those	 describe	 in	 the	
abovementioned	steps	must	be	carefully	assessed	from	a	large	panel	of	experts,	
including	 the	 medical	 community,	 the	 patients,	 and	 the	 governmental	
stakeholders.	The	latter	is	of	utmost	importance	in	the	case	of	Genomic	Medicine	
interventions,	where	policy	makers	with	high	power	of	intervention,	such	as	the	





only	 showed	 a	marginal	 difference	 in	QALYs	 between	PGx-	 vs	 non	 PGx-guided	
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morbidity,	mortality,	 and	–	 consequently	 –	 the	 level	 of	 health	 care	provided	 in	
every	 country.	 This	 is	 of	 particular	 interest	 in	 developing	 countries	where	 the	
resources	are	limited	and	must	be	spent	wisely	to	address	social	justice	and	the	





medicine,	 based	 on	 performance	 ratio,	 with	 potential	 applications	 in	 diverse	
health	care	sectors,	which	is	particularly	appealing	for	developing	countries	and	
low-resource	 environments.	 The	 model	 proposes	 a	 new	 method	 for	 resource	
allocation	taking	into	account	a)	the	size	of	innovation	of	a	new	technology,	b)	the	
relative	 effectiveness	 in	 comparison	with	 social	 preferences,	 c)	 the	 cost	 of	 the	
technology,	 while	 permits	 the	measurement	 of	 effectiveness	 to	 be	 determined	
differently	in	the	context	of	a	specific	disease	and	then	to	be	expressed	in	a	relative	
form	via	a	common	performance	ratio.	The	present	work	expands	upon	previous	
works	 by	 the	 authors	 and	 in	 the	 literature	 for	 innovation	 in	 economic	models	






















targeting	 evidence	 gaps	 for	 public	 health	 genomics	 priorities	 so	 that	 not	 only	
clinicians	 are	 persuaded	 for	 the	 need	 to	 implement	 genome-guided	 decision	
making,	but	also	policymakers	and	regulators	for	the	need	to	adopt	and	reimburse	
genomic	 tests	 from	 insurance	 funds	 (Vozikis	 et	 al.,	 2016),	 and	 to	 prioritize	
research,	 development	 and	 innovation	 in	 all	 Genomic	 Medicine	 disciplines	
(Snyder	et	al.,	2014).		
Economic	evaluation	aims	to	assess	whether	a	new	health	care	technology	
or	 interventions	 provides	 “value	 for	money”	 in	 terms	 of	 costs	 and	 therapeutic	
consequences	compared	to	existing	interventions	(Fragoulakis	et	al.,	2016).	The	
most	common	research	approach	employed	by	policymakers	to	assess	the	value	








same	 clinical	 problem/client	 group	 (the	 incremental	 cost)	 divided	 by	 the	
difference	in	outcomes	between	the	new	intervention	and	the	current	approach	
(the	incremental	effects).	If	ICER	is	below	a	pre-determined	amount	a	policymaker	
is	 willing	 to	 pay	 for	 an	 additional	 unit	 of	 effectiveness	 (the	 desirable	 medical	
outcomes),	the	new	intervention	called	a	“cost-effective	option”	and	meets	one	of	















and	Birch,	 (2006).	 Indeed,	 the	 classical	 theory	 assumes	 that	 all	 “cost-effective”	









Enzing,	 2014)	 but	 its	 criteria	 for	 the	 final	 verdict	 concerning	 the	 adoption	 or	
rejection	 of	 a	 new	 health	 technology	 remains	 unclear.	 Also,	 there	 are	 other	
drawbacks	in	this	analysis.	First	of	all,	to	adopt	a	new	intervention	the	decision-
maker	 must	 withdraw	 some	 existing	 interventions	 in	 order	 to	 find	 enough	
resources	 to	 support	 the	 new	 ones.	 However,	 in	 practice,	 very	 few,	 if	 any,	
economic	evaluations	state	explicitly	which	specific	health	 technologies	and/or	
interventions	must	be	withdrawn	 to	meet	 the	budget	 criteria	 (Birch	and	Gafni,	
2006).	 In	 addition,	 the	 classical	 theory	 assumes	 that	 all	 decrementally	 cost-
effective	 options	 (less	 costly,	 less	 effective	 but	 within	 the	 willingness-to-pay	
threshold;	 Nelson	 et	 al.,	 2011),	 could	 be	 reimbursed	 based	 on	 cost	 criteria.	




treatment	 of	 patients	which	make	 the	 possibility	 to	 adopt	 an	 alternative	 “very	
poor”,	in	terms	of	effectiveness,	technology	and/or	intervention	highly	unlikely,	
despite	their	cost-saving	profile.	Furthermore,	the	classical	model	assumes	that	
the	 willingness-to-pay	 for	 a	 unit	 of	 effectiveness	 is	 independent	 of	 the	 actual	
difference	in	effectiveness	between	different	health	technologies	and	thus,	does	
not	 differentiate	 between	 a	 new	 truly	 innovative	 health	 technology,	 a	 similar-
with-the-current	 health	 technology,	 or	 even	 a	 generic	 health	 technology	 and	












to	 resolve	 these	 aforementioned	drawbacks	 (Fragoulakis	 et	 al.,	 2016).	Genome	
Economics	Model	(GEM)	implies	that	there	is	a	maximum	amount	of	money	per	
patient	that	could	be	spent	by	the	payers	only	if	a	certain	therapeutic	gain	from	an	
innovative	 health	 technology	 was	 met	 by	 health	 providers.	 As	 such,	 in	 sharp	
contrast	with	the	classical	cost-effectiveness	approach,	under	the	GEM	approach,	
the	 insurance	 funds	 define	 ex-ante	 what	 is	 expected	 to	 be	 the	 upper	 limit	 of	
‘‘innovation’’	in	terms	of	effectiveness/QALY	gains,	what	is	the	lowest	acceptable	
effectiveness	 that	 could	 be	 accepted	 and	 judge	 ex-post	 every	 new	 technology	
within	two	boundaries.	In	addition,	GEM	defines	the	maximum	amount	of	money	
is	willing	to	invest	or	save	the	budget	holder	within	two	boundaries.	Furthermore,	
the	 GEM	 model,	 contrary	 to	 the	 classical	 model,	 does	 not	 conduct	 a	 separate	





actual	 incremental	 effectiveness	 of	 a	 new	 intervention,	 in	 correlation	with	 the	
willingness	to	pay	for	a	QALY	in	a	formal	manner	(for	mathematical	details	see	Yin	
et	al.,	2003).	In	this	context,	every	potentially	new	unit	of	effectiveness	that	could	
be	 gained	 from	 future	 technologies	 has	 a	 different	 perceived	 value	 by	 policy	
makers.	For	a	very	small	difference	between	two	health	technologies,	the	average	
willingness	to	pay	for	a	QALY	is	expected	to	be	low	due	to	low	additional	value.	




average	willingness	 to	 pay	 for	 every	 unit	 of	 QALY	 is	 expected	 to	 be	 higher	 in	
comparison	 with	 classical	 model.	 As	 the	 difference	 in	 effectiveness	 increases	
further	(breakthrough	technology),	we	meet	the	budget	constraints	criteria	and,	
as	 such,	 we	 are	 unable	 to	 reimburse	 this	 technology	 further	 and	 the	 average	
willingness	to	pay	is	getting	lowered.	The	shape	of	willingness	to	pay	for	a	QALY	
resembles,	 as	 the	 potential	 difference	 in	 effectiveness	 increases,	 a	 bell-shape	




issue	 of	 health	 resource	 allocation	 problem.	 Indeed,	 in	 this	 model	 a	 far	 less	
ambiguous	 approach	 was	 adopted	 to	 estimate	 the	 local	 equilibrium	 which	 is	
driven	 by	 the	de	 facto	 budget	 availability	 in	 a	 disease-specific	 context	without	
taking	into	account	QALYs	from	different	therapeutic	areas.	Hence,	all	conclusions	
and	contributions	of	the	GEM	model	were	referred	to	a	specific	disease	context	
without	 any	 comparisons	 with	 other	 therapeutic	 areas.	 To	 deal	 with	 such	
challenges,	 the	 identification	 of	 effectiveness,	 and	 consequently	 the	 amount	 of	
willingness	 to	 pay,	 could	 be	 attained/determined	 by	 ranking	 the	 available	







The	 aim	 of	 the	 present	 model	 is	 to	 propose	 an	 alternative	 method	 for	











account	 the	 uncertainty	 of	 variables	 (Briggs	 et	 al.,	 1994)	 and	 consequently	









The	model	 is	 developed	 in	 a	 6-step	 approach	 (Fig.	 8.1).	 First	 of	 all,	 the	
decision	makers	must	identify	all	the	available	health	technologies	(comparators)	
within	 different	 disease	 specific	 areas.	 These	 choices	 must	 include	 the	 “most	
expensive”,	the	“least	costly”,	and	the	“gold	standard”	intervention,	which	must	be	
set	 in	 accordance	 with	 the	 standard	 medical	 practice,	 the	 literature	 and	 the	
current	scientific	research	(Drummond	et	al.,	1997).	It	must	be	noted	that	specific	
attention	 has	 to	 be	 given	 to	 this	 step,	 since	 some	 health	 care	 technologies	 are	














2013).	 Subsequently,	 the	decision	maker	has	 to	define	how	effectiveness	 in	 its	
separate	disease-specific	context	needs	to	be	determined.	For	instance,	 in	GEM,	
there	is	no	mandatory	rule	to	express	the	effectiveness	via	the	common	measure	




(Schwappach,	 2002).	 Thus,	 several	 different	 disease-specific	 (but	 one-






available	 health	 technologies	 are	 expressed	 [as	 “Cost”	 (€,	 £,	 $),	 “Effectiveness”	
(PFS),	etc)],	then	the	second	step	of	the	model	is	completed.		
The	third	step	in	the	alternative	model,	proposed	herein,	is	to	set	ex-ante	




and	must	 be	 set	 in	 every	 therapeutic	 area	 by	 the	 corresponding	 scientific	 and	
medical	societies.	This	“ΔΕmax”,	has	to	be	expressed,	as	mentioned,	in	the	terms	
of	 this	particular	 tool	used	 in	every	area.	 It	must	be	noted	that	 in	a	developing	






action	 must	 be	 taken	 into	 account,	 if	 (a)	 it	 constitutes	 an	 sound	 alternative	
enabling	greater	precision	 to	 individual	patient	needs,	 (b)	 and	 to	which	extent	
improves	 patient	 compliance	 through	 better	 dosage	 and	 administration	mode,	
and	 (c)	 it	 extends	 the	 indications	 and	 gives	 multiple	 options	 in	 the	 same	




to	 meet	 the	 maximum	 incremental	 effectiveness.	 This	 step	 follows	 a	 similar	




























the	willingness	 to	 pay	 for	 a	 unit-of-effectiveness	 in	 correlation	with	 the	 actual	
difference	produced	by	every	new	health	technology.	This	non-linear	function	for	
willingness	to	pay	drives	healthcare	providers	to	increase	the	effort	for	favourable	
treatments,	 ‘‘punishes’’	 the	 less	 productive	 ones,	 and	 ‘‘rewards’’	 those	









Lastly,	 the	proposed	new	model	defines	a	 “performance	 ratio”	 for	every	
available	technology,	which	is	determined	by	the	“one	minus	the	ratio	of	the	actual	
incremental	 cost	of	a	new	 technology	divided	by	 the	willingness	 to	pay	 for	 the	
actual	effectiveness	gained”	by	this	specific	technology.	If	this	ratio	is	negative,	the	
policy	makers	are	not	willing	to	adopt	and	rejects	this	technology,	since	the	cost	
of	adoption	 is	greater	 than	what	are	 they	willing	 to	 invest.	Of	course,	 the	most	

















Finally,	 as	 a	 rule,	 the	 available	 resources	 will	 be	 spent	 for	 those	
technologies	which	provide	the	most	attractive	performance	across	the	healthcare	
sector	 with	 a	 mathematical	 programming	 type	 of	 analysis	 until	 the	 budget	 is	
exhausted	(Flessa,	2000).	This	model	assumes	that	the	policy	makers	are	willing	
to	maximize	this	performance	ratio	of	health	gains,	and	not	to	maximize	QALYs	as	
it	 is	 the	 normal	 (Weinstein	 et	 al.,	 2009).	 Hence	 in	 this	 model,	 the	 aspect	 of	
innovation	has	two	different	and	distinct	dimensions:	(a)	the	actual	difference	in	
effectiveness	which	is	on	behalf	of	the	patient	in	correlation	with	what	is	expected	





With	 this	 model,	 all	 health	 technologies	 (“me-too”,	 “fair”,	 “innovative”,	 “very	
innovative”,	 “breakthrough”)	 in	 all	 specific	 areas	 become	 comparable	 via	 the	
“performance	ratio”	and	thus	the	model	provide	a	ground	for	comparisons	(and	
reimbursement)	 amongst	 them.	 Of	 course,	 in	 order	 to	 meet	 meaningful	
conclusions,	the	model	requires	the	explicit	mapping	of	preferences	via	the	non-
linear	forms	of	willingness	to	pay	in	a	quantitative	form.		
It	 must	 be	 noted	 that	 in	 accordance	 with	 the	 maximization	 rule	 of	
performance	ratio,	the	model	gives	a	“premium”	in	innovative	technologies	and	
permit	 them	 to	 absorb	 proportionally	 higher	 amount	 of	 budget	 in	 comparison	
with	a	simple	linear	approach	of	classical	model.	In	other	words,	for	innovative	
interventions	 (in	 terms	of	 effectiveness),	 there	 is	 a	 higher	 reimbursement	 as	 a	
reward	for	the	successful	research-and-development	process,	while	the	model	is	





Understanding	 the	 relative	 benefits	 and	 drawbacks	 of	 alternative	






Here,	 we	 have	 proposed	 an	 alternative	 methodological	 concept	 for	
resource	allocation	which	represents	the	generalization	of	a	previously	published	
work	 (Fragoulakis	 et	 al.,	 2016)	 and	 could	be	particularly	useful	 for	developing	
countries.	In	the	present	work,	it	has	been	argued	that	“innovation”	must	be	set	as	
a	priority	and	this	term	might	also	include:	(a)	the	absolute	benefit	on	behalf	of	
the	 patients,	 and	 (b)	 the	 ratio	 of	 cost	 and	 effectiveness	 in	 terms	 of	 “social	
consumer	surplus”.	In	order	to	avoid	theoretical	issues	with	the	use	of	QALY	which	
is	still	under	consideration	(Wailoo	et	al.,	2009;	Baker	et	al.,	2010;	Lancsar	et	al.,	





as	 percentage)	 in	 accordance	 with	 social	 preferences.	 In	 this	 light,	 we	 have	
avoided	the	use	of	QALYs,	despite	the	fact	that	it	is	possible	to	be	also	used	as	the	
variable	which	can	be	maximized	in	the	present	model.	In	that	sense,	the	model	
maximizes	a	unified	 theoretical	and	abstractive	 index	which	 takes	 into	account	
three	different	“variables”:	namely	the	cost,	the	effectiveness	and	its	size,	and	the	




the	 potential	 value	 of	 the	 present	 model	 must	 be	 judged	 in	 comparison	 with	
similar	 attempts	 previously	 made	 (Eckermann	 et	 al.,	 2008;	 see	 also	
www.york.ac.uk/che/pdf/mathprog.pdf).	In	the	most	of	cases	the	analysis	of	this	






























tool,	 but	 despite	 the	 attractive	 veneer	 of	 objectivity	 given	 by	 the	 concise	 and	






warrant	 practical	 implementation.	 In	 summary,	 the	 main	 methodological	
























































































































































































































the	 potential	 to	 become	 an	 integral	 part	 of	 modern	 clinical	 practice.	
Pharmacogenetics	aims	to	deliver	“the	right	drug	to	the	right	patient	at	the	right	






society	 overall.	 The	 availability	 of	 economic	 evaluation	 studies	 of	
pharmacogenomic-guided	 interventions	and	of	 specialized	or	generic	economic	
models	to	perform	such	studies,	will	be	key	in	the	efforts	to	generate	evidence	for	
the	 clinical	 utility	 of	 these	 interventions.	 This	will	 allow	healthcare	 systems	 to	
reimburse	pharmacogenomic	testing	costs,	particularly	since	the	testing	costs	are	
gradually	 declining.	 At	 the	 same	 time,	 a	 critical	 appraisal	 of	 the	 views	 of	 the	
various	 stakeholders	 involved	 in	 the	 provision	 of	 pharmacogenetics	 and	
personalized	medicine	interventions	is	of	equal	importance	to	smoothen	the	way	
of	pharmacogenetics	into	the	clinic.	
Consistent	 with	 the	 challenges	 outlined	 above,	 this	 thesis	 aimed	 to	 (i)	
economically	 evaluate	 pharmacogenomic-based	 drug	 treatment	 modalities	 to	
demonstrate	their	cost-effectiveness,	(ii)	to	develop	economic	models	that	could	
be	 used	 to	 perform	 these	 economic	 evaluation	 studies,	 and	 (iii)	 to	 critically	
appraise	the	current	views	and	opinions	of	the	healthcare	professionals	and	the	
various	 other	 stakeholders	 in	 the	 provision	 of	 pharmacogenetics	 services.	
Particular	 focus	 was	 given	 into	 developing	 countries	 and	 low-resource	











cost-effectiveness.	 As	 previously	 mentioned,	 economic	 evaluation	 studies	 of	
pharmacogenetics-guided	 treatment	modalities	 are	 very	 scarce.	 Particularly	 in	
developing	nations	and	low-resource	environments,	a	cost	saving	approach	using	
pharmacogenomic	 information	 could	 be	 valuable.	 Hence,	 we	 have	 decided	 to	




Warfarin	 is	 the	 mainstream	 drug	 treatment	 modality	 for	 patients	 with	
atrial	 fibrillation.	 Our	 analysis	 showed	 that	 pharmacogenomic-guided	warfarin	
treatment	using	the	CYP2C9/VKORC1	genotypes	is	a	cost-effective	option	for	those	
suffering	from	atrial	fibrillation	and	developed	ischemic	stroke.	Our	findings	were	




but	 there	 was	 a	 clear	 health	 gain	 demonstrated	 for	 these	 patients:	 less	
complications	 due	 to	 bleeding	 and	 a	 shorter	 time	 to	 reach	 the	 required	
maintenance	 dose.	 Overall,	 this	 analysis	 indicated	 that	 in	 Croatia,	
pharmacogenetic-guided	 warfarin	 treatment	 may	 constitute	 a	 cost-effective	
treatment	modality	and	was	assessed	for	the	management	of	elderly	patients	with	
atrial	 fibrillation	who	 developed	 ischemic	 stroke	 as	 compared	 to	 conventional	










coworkers	 (2016),	 who	 also	 showed	 that	 pharmacogenetic-guided	 dosing	 of	
warfarin	is	a	cost-effective	strategy	to	improve	outcomes	of	patients	with	atrial	
fibrillation	 in	 Sweden	 too.	 On	 the	 contrary,	 Verhoef	 and	 coworkers	 (2015)	
assessed	 the	 cost-effectiveness	 of	 pharmacogenetically-guided	 acenocoumarol	
and	 phenprocoumon	 treatment	 and	 showed	 that	 with	 ICER	 of	 €28,349	 and	
€24,427	per	QALY	gained,	respectively,	these	treatment	modalities	are	unlikely	to	
be	 cost	 effective	 compared	 with	 the	 clinical	 dosing.	 Availability	 of	 low-cost	
genotyping,	 however,	would	make	 this	 a	 cost-effective	 option.	 Similarly,	 in	 the	
United	 States,	 Meckley	 and	 coworkers	 (2010)	 showed	 that	 warfarin	
pharmacogenomic	 testing	may	provide	 a	 small	 clinical	 benefit	with	 an	 ICER	of	
<50000	USD	per	QALY,	with	the	results	being	sensitive	to	the	genotyping	costs. 
As	 far	 as	 the	 pharmacogenetically-guided	 clopidogrel	 treatment	 is	
concerned,	we	 retrospectively	 assessed	whether	CYP2C19	 genotyping	 could	 be	
cost-effective	 in	order	 to	determine	 the	optimal	antiplatelet	 therapy	 in	Serbian	
patients	 treated	 with	 clopidogrel,	 as	 compared	 to	 the	 non-genotype-guided	
treatment	 (see	Chapter	 6).	 Again,	 an	 almost	 5-fold	 higher	 rate	 of	 reinfarction	





break-even	 point	 analysis,	 performing	 the	 genetic	 test	 prior	 to	 prescribing	
clopidogrel	represents	a	cost-saving	option,	saving	€13	per	patient	on	average	in	
combination	 with	 a	 better	 health	 outcome.	 Also,	 considering	 the	 fact	 that	
treatment	with	 ticagrelor,	 the	 alternative	 treatment	modality	 to	 clopidogrel,	 is	
around	€300	more	expensive	per	patient,	 the	use	of	 the	 former	 is	 justified	 for	






When	 assessing	 cost-effectiveness	 of	 clopidogrel	 treatment	 in	 the	 US	
healthcare	 system,	 Lala	 and	 coworkers	 (2013)	 showed	 that	 acute	 coronary	
syndrome	patients	undergoing	PCI,	a	pharmacogenetically-guided	strategy	yields	
almost	similar	outcomes	compared	to	conventional	treatment	modalities,	being	
only	marginally	 less	 costly	 and	more	 effective.	 On	 the	 contrary	 Jiang	 and	 You	
(2016)	showed	that	in	the	US	healthcare	system,	clopidogrel	treatment	was	the	










found	 to	be	 cost	 effective	and	 the	 same	was	 true	 for	both	 studies	 involved	 the	
Australian	healthcare	system,	in 3	out	of	4	studies	originating	from	Canada	and	3	
out	of	6	studies	from	the	Netherlands.	Interestingly,	findings	from	the	remaining	
countries,	 namely	 9	 out	 of	 10	 studies	 (90%),	 included	 in	 this	 study	 also	
demonstrated	 cost-effectiveness	 of	 the	 pharmacogenetics	 -guided	 treatment	
modalities	in	cardiology.	
These	results	generated	for	the	need	of	this	thesis	are	applicable	only	for	





In	 addition,	 these	 analyses	 could	be	 repeated	periodically,	 especially	when	 the	
comparators	change	over	time.		
Although	economic	evaluation	studies	and	cost-effectiveness	analyses	of	







of	 colorectal	 cancer	 patients	 was	 assessed	 is	 Germany	 (Behl	 et	 al.,	 2012)	 and	
Austria	(Königsberg	et	al.,	2012),	indicating	that	the	genome-guided	intervention	
was	 cheaper	 and	 with	 the	 same	 effectiveness.	 The	 same	 intervention	 in	
Switzerland	was	shown	to	be	cost-effective	(Blank	et	al.,	2011).	In	the	case	of	DPYD	
genotyping	for	the	treatment	of	colorectal	cancer	patients	with	capecitabine	and	
fluorouracil,	 this	 was	 also	 shown	 to	 be	 slightly	 cheaper	 for	 the	 Netherlands	
(Deenen	 et	 al.,	 2015)	 and	 also	 a	 dominant	 choice	 (cheaper	 and	 with	 better	
effectiveness)	 in	 Italy	 (Fragoulakis	 et	 al.,	 2019b),	 respectively.	 Genome-guided	
treatment	of	colorectal	cancer	patients	with	irinotecan	monotherapy,	based	on	the	
UGT1A1*28	genotype	was	also	 shown	 to	be	a	dominant	 choice	 for	African	and	




In	 neurology,	 a	 key	 example	 is	 the	 cost-effectiveness	 analyses	 of	 HLA-
B*1502-based	carbamazepine	treatment	of	patients	with	epilepsy.	This	variant	is	
more	 prevalent	 in	 Asian,	 compared	 to	 Caucasian	 and	 African	 populations.	 In	
Singapore,	a	cost-effectiveness	analysis	involving	all	three	ethnic	groups	bearing	
different	allele	frequencies	of	the	HLA-B*15:02	allele,	indicated	that	HLA-B*15:02-
based	 carbamazepine	 treatment	 was	 cost-effective	 in	 all	 three	 subpopulations	
(Dong	et	al.,	2012;	Liew,	2016).	
In	 case	 of	 infectious	 diseases,	 there	 are	 also	 few	 economic	 evaluation	
studies	 previously	 performed.	 In	 HIV	 treatment,	 patients	 who	 carry	 the	HLA-
B*57:01	 allele	 are	 at	 high	 risk	 for	 experiencing	 a	 hypersensitivity	 reaction	 to	
abacavir	 [Mallal	 et	 al.,	 2008].	 The	 first	 economic	 evaluation	was	 performed	 in	
2004	by	Hughes	and	coworkers,	indicating	that	the	HLA-B*57:01	testing	strategy	
ranged	 from	 dominant	 (less	 expensive	 and	 more	 beneficial	 compared	 to	 no	






shown	that	 IL28B	 genetic	variants	can	predict	 treatment	response	with	certain	
variants	 leading	 to	 a	 less	 favorable	 response.	 Bock	 and	 coworkers	 (2014)	
demonstrated	that	IL28B-guided	therapy	is	cost-effective	for	each	IL28B	variant	
compared	to	the	standard	of	care	therapy	for	HCV	genotype	2	and	3	patients.		




Economic	 evaluation	 is	 a	 key	 component	 in	 rationalizing	 healthcare	
expenditure,	as	the	provision	of	optimal	healthcare	solutions	is	one	of	the	leading	
priorities	 in	 society.	An	uncontrolled	 growth	 in	health	 care	 expenditure	would	
affect	the	national	budget.	Economic	evaluation	provides	a	criterion	for	the	final	




In	 this	 thesis,	 we	 propose	 two	 alternative	 methodological	 approaches,	
which	 take	 into	consideration	 the	budget	constraint,	 the	effectiveness	of	a	new	
technology	and	social	preferences.		
The	 first	 model	 (Genome	 Economics	 Model,	 GEM)	 describes	 the	 link	
between	the	willingness	to	pay	threshold	towards	the	budget	limit,	enabling	the	
combination	of	cost-effectiveness	and	budget	impact	analysis	(see	Chapter	7	for	
term	definitions).	 In	 this	 context,	 every	new	unit	of	 effectiveness	 that	 could	be	
potentially	 gained	 from	 the	 innovative	 technologies	 has	 a	 different	 perceived	
value	 for	 the	 patients,	 the	 scientific	 community	 and	 the	 stakeholders.	 In	 other	
words,	if	the	difference	in	effectiveness	between	two	health	technologies	is	very	





interventions,	 then	 this	new	 intervention	can	be	reimbursed,	provided	 that	 the	
reimbursement	costs	are	well	within	the	budget	constraints	criteria.	Hence,	the	
new	model	encourages	healthcare	providers	to	increase	the	effort	for	favorable	
treatments,	 “punishes”	 the	 less	 productive	 ones	 and	 “rewards”	 the	 true	
innovation,	ensuring	at	the	same	time	the	sustainability	of	the	healthcare	system.	
This	model	also	attempts	to	unify	cost-effectiveness	and	budget	impact	analysis,	
also	 taking	 into	 serious	 consideration	 ethical	 issues	 and	 patients’	 preferences,	
improving	 some	core	drawbacks	of	 other	models.	Despite	 the	potential	 added-
value	and	novelty	of	the	GEM	model,	it	does	not	address	the	very	important	issue	
of	health	resource	allocation.	To	deal	with	such	challenges,	 the	 identification	of	
effectiveness,	 and	 consequently	 the	 amount	 of	 willingness	 to	 pay,	 could	 be	
determined	 by	 ranking	 the	 available	 interventions	 for	 all	 diseases	 under	 a	
resource	constraint	with	the	use	of	a	mathematical	programming-type	technique	
(Sendi	et	al.,	2002).		
As	 such,	we	designed	an	alternative	method	 for	 resource	allocation	 that	
takes	into	consideration	a)	the	incremental	innovation	of	a	new	technology,	b)	the	
relative	 effectiveness	 in	 comparison	with	 social	 preferences,	 c)	 the	 cost	 of	 the	




which	 determines	 the	 proportional	 increase	 in	 effectiveness	 (the	 relative	
effectiveness	as	percentage)	in	accordance	with	social	preferences.	In	essence,	this	


















In	 order	 to	 maximize	 the	 benefits	 of	 economic	 evaluation	 studies	
mentioned	in	the	previous	paragraphs	and	to	expedite	pharmacogenetics-guided	
treatment	 interventions	 into	 the	 clinic,	 one	 should	ensure	 that	 the	 stakeholder	
environment	 in	 every	 country	 is	 clearly	 explored	 and	 the	 views	 of	 the	 various	
stakeholders	critically	appraised.		
Given	the	potential	of	genomic	medicine	to	grow	in	the	coming	years,	it	is	
imperative	 to	 comprehensively	 analyze	 the	 level	 of	 awareness	 of	 healthcare	
professionals	 in	 relation	 to	 genomics	 and	 personalized	 medicine	 so	 that	 the	
delivery	 of	 genomic	 services	 may	 be	 expedited	 in	 their	 various	 healthcare	
systems.	Genetics	 education	 and	 communication	will	 play	 an	 important	 role	 in	
increasing	 the	 level	 of	 awareness	 of	 the	 various	 stakeholders	 with	 respect	 to	
genomic	 medicine	 so	 that	 they	 come	 to	 appreciate	 the	 benefits	 that	 this	 new	
discipline	can	offer	(Reydon	et	al.,	2012).			
In	 this	 thesis,	we	attempted	 to	 shed	 light	on	 the	 level	of	 awareness	and	





contrary	 to	 other	 Western	 European	 countries	 where	 Genomic	 Medicine	










Genomes	 projects,	 respectively,	 there	 are	 well-established	 online	 resources	 to	
educate	 healthcare	 professionals	 in	 the	 fields	 of	 genomic	 medicine	 and	
pharmacogenetics	 (https://allofus.nih.gov,	
https://www.genomicsengland.co.uk/understanding-genomics).	 In	 the	 United	
Kingdom,	integral	to	the	success	of	the	100,000	Genomes	Project	is	the	education	
and	training	of	both	the	healthcare	workforce	and	patients	and	the	public.	This	




changing	 genomics	 and	 stratified	medicine	 landscape,	 and	 (c)	 provide	 broader	
prospective	 workforce	 transformation	 for	 the	 NHS	 and	 Public	 Health.	 The	
dedicated	M.Sc.	program	that	HEE	has	commissioned	to	seven	leading	universities	
in	 the	 United	 Kingdom,	 which	 is	 especially	 suitable	 for	 doctors,	 healthcare	
professionals	and	students	with	an	interest	in	genetics	and	genomics,	is	another	




comparable	 to	 the	pharmacists	who	admitted	very	 limited	or	no	knowledge	of	
pharmacogenomics	 and	 its	 relationship	 with	 personalized	 medicine.	 A	 small	
proportion	 (5%)	 of	 pharmacists	 in	 Greece	 felt	 that	 their	 genetics	 and	
pharmacogenomics	knowledge	was	high.	As	far	as	physicians	are	concerned,	24%	

















Proper	 continuous	 pharmacogenomics	 education	 must	 be	 encouraged	 to	 help	






policymaking,	 using	 Policy	Maker’s	 computerized	 version	 of	 political	mapping.	
Based	 on	 this	 analysis,	 the	 Current	 Position	 Map	 of	 these	 stakeholders	 was	
generated,	 according	 to	 the	 extent	 of	 their	 support	 or	 opposition	 to	




influence	 and	 are	 driving	 forces	 to	 support	 clinical	 implementation	 of	
pharmacogenomics	 from	a	 technology-driven	point	of	view.	On	the	other	hand,	
there	was	a	medium	opposition	from	the	Ministry	of	Health	and	the	public	health	
insurance	 funds,	 based	 on	 not	 yet	 fully	 proven	 cost	 effectiveness	 of	 a	
pharmacogenomics	approach,	both	of	which	have	high	power	to	intervene	against	













2014)	 could	 also	 explain	 the	 medium	 opposition	 of	 these	 stakeholders.	 The	
neutral	 position	 of	 the	 Greek	 National	 Medicines	 Organization	 and	 the	 highly	
supportive	position	of	 the	private	health	 insurance	companies	were	surprising,	
considering	the	fact	that	they	both	are	at	the	opposite	direction	compared	to	that	
of	 the	 public	 health	 insurance	 funds.	 This	 warrants	 further	 investigation	 and	




highly	 supportive	 towards	 genomic	 medicine	 and	 individualization	 of	 drug	
treatment,	 despite	 the	 fact	 that	 they	 professed	 that	 their	 level	 of	 genetics	
awareness	is	fairly	low.	The	neutral	position	held	by	the	Media	and	the	Press	could	
be	attributed	to	their	lack	of	knowledge	and	hence,	if	objective	opinions	and	facts	
are	 presented	 by	 academics,	 qualified	 professionals,	 and	 regulatory	 bodies,	 it	
would	 help	 them	 towards	 adopting	 a	 more	 positive	 stance	 towards	 genomic	
medicine	 and	 pharmacogenomics,	 providing	 extra	 help	 to	 alter	 the	 position	 of	
governmental	 organizations	 that	 are	 currently	 opposed	 to	 genomic	 medicine,	
mostly	 due	 to	 the	 financial	 constrain	 imposed	 by	 the	 high	 fiscal	 deficit	 in	 the	
country.			
Apparently,	 once	 the	 first	 tangible	 benefits	 from	 the	 implementation	 of	
pharmacogenomics	become	available,	and	more	evidence	regarding	the	value	of	
genome-guided	 interventions	 is	 produced,	 the	 overall	 position	 of	 these	 key	
stakeholders	will	most	 likely	 change	 to	 a	more	 favorable	 one.	 In	 any	 case,	 the	
results	of	 this	approach	can	not	only	help	 to	adopt	certain	steps	and	measures	
necessary	to	maintain	the	overall	positive	attitude	of	most	stakeholders	towards	













Pharmacogenomics	 can	 clearly	 contribute	 to	 minimize	 adverse	 drug	
reactions	and,	as	a	result,	help	reducing	morbidity	and	mortality	rates.	There	are	
several	studies	that	have	highlighted	the	role	of	genomic	variants,	based	on	which	
the	 drug	 dose	 can	 be	 individualized	 in	 patients	 receiving	 medication	 for	
cardiovascular,	oncological,	psychiatric	and	other	diseases.	In	order	to	implement	
a	 genome-guided	 treatment	 strategy,	 economic	 evaluations	 and	 cost	 benefit	
analyses	are	required.	Generally,	the	need	to	perform	cost-benefit	analyses	stems	
from	 the	 scarcity	 of	 resources	 in	 order	 to	 set	 priorities	 in	 the	 investments	 for	
health	 care.	 These	 benefits	 should	 be	 evaluated	 by	means	 of	 proper	 economic	
analysis,	 taking	 into	 consideration	 ethical	 and	 societal	 issues	 as	 well	 as	 the	
available	budget.	This	stepwise	approach	performed	in	this	thesis	could	serve	as	
an	 excellent	 model	 for	 replication,	 also	 and	 especially	 in	 low-resource	
environments.	This	can	be	particularly	challenging,	since	results	from	medical	and	
genomics	research	are	often	considered	as	intermediate	indicators	and	should	be	
converted/translated	 into	 tangible,	 final	 health	 outcomes	 on	which	 policy	 and	
decision	makers	are	based	to	draw	their	conclusions	as	to	which	intervention	to	
adopt	 and	 reimburse.	 This	 economic	 evaluation	 process	 has	 been	 reported	 in	
Chapters	 5	 and	 6	 to	 indicate	 that	 genome-guided	 warfarin	 and	 clopidogrel	
treatment	is	cost-effective	in	Croatia	and	Serbia,	respectively.		
We	have	also	proposed	alternative	models	to	perform	economic	evaluation	





serious	 consideration	 social	 preferences	 and	 acceptability	 of	 new	 technologies	
and	 rewards	 innovation.	 These	 models	 are	 particularly	 relevant	 to	
pharmacogenomics	 and	 genomic-guided	 interventions,	 since	 the	 latter	
interventions	 are	 highly	 innovative.	 As	 such,	 we	 propose	 that	 resources	 are	
transferred	from	existing	low-innovation	interventions,	such	as	the	conventional	






their	 stance	 towards	 genomic	 medicine.	 At	 the	 moment,	 the	 vast	 majority	 of	
stakeholders	 are	 generally	 positive	 but	 continuous	 medical	 education	 and	
awareness	is	needed	not	only	to	maintain	this	position	but	also	to	better	inform	





technologies.	 This	 would	 provide	 the	 basis	 to	 encourage	 additional	 economic	
evaluation	studies,	which	would	yield	more	positive	results	regarding	 the	cost-
































































































































































































































































The	 central	 aim	 of	 Personalized	 Medicine	 is	 to	 exploit	 the	 individual’s	





In	 1956,	 Fredrich	 Vogel	 introduced	 the	 term	 “Pharmacogenetics”	 when	
describing	 the	 adverse	 effect	 of	 soldiers	 on	 primaquine,	 an	 antimalarial	 drug,	
appeared	to	be	the	result	of	a	genetic	defect	in	the	G6PD	enzyme.	In	1962,	Evans	
and	 coworkers	 described	 the	 genetic	 backround	 of	 peripheral	 neuropathy	
occuring	when	patients	where	treated	with	isoniazide,	and	linked	this	response	to	





population	 has	 a	 low	 activity	 of	 this	 enzyme,	 whereas	 2-4%	 has	 an	 increased	
activity,	 all	 due	 to	 different	 CYP2D6	 genomic	 variants.	 In	 1985,	 Richard	
Weinshilboum	 reported	 the	 hereditary	 component	 of	 the	 thiopurine	 S-methyl	
transferase,	 which	 was	 subsequently	 linked	 to	 genetic	 variants	 in	 the	 TPMT	
(thiopurinemethyltransferase)	gene.		
The	 term	 used	 for	 this	 field	 is	 “Pharmacogenetics”,	 that	 is	 the	 relation	
between	 hereditary	 factors	 and	 drug	 metabolizing	 capacity.	 Later,	 the	 term	
“Pharmacogenomics”	 was	 introduced,	 covering	 pharmacogenetics,	 but	 also	
including	 other	 genomic	 variants	 identified	 in	 the	 genome	 as	 well	 as	 mRNA	
expression	profiles	affecting	drug	metabolism.		











increasingly	 budget-scarce	 environment.	 It	 is	 often	 argued	 that	 personalizing	
treatment	will	inevitably	improve	clinical	outcomes	for	patients	and	help	achieve	




such,	 it	 will	 be	 used	 as	 an	 example	 to	 highlight	 the	 application	 of	 economic	
evaluation	in	Personalized	Medicine.	Pharmacogenomics	attempts	to	enrich	our	
understanding	 of	 how	 medicines	 work	 in	 each	 individual	 based	 on	 genomic	
contributions	 to	a	medicine’s	 safety	and	efficacy.	The	 latter	 can	 lead	 to	a	more	
efficient	 and	 effective	 approach	 to	 drug	 discovery.	 Furthermore,	




variations	 on	 drug	 response,	 in	 terms	 of	 both	 drug	 metabolism	
(pharmacokinetics)	 and	drug	action	 (pharmacodynamics).	Additionally,	 genetic	




there	are	genetic	 factors	 that	account	 for	20-95%	of	the	observed	responses	to	
drug	therapies,	one	could	understand	the	impact	of	this	new	discipline	in	modern	
medicine.	It	is	important	to	note	that	other	factors	such	as	age,	food	intake,	drug-





guided	 treatment	 interventions,	 in	comparison	with	 the	standard	 interventions	
used	 in	 the	 current	 medical	 practice.	 We	 focus	 on	 the	 economic	 analysis	 of	
pharmacogenomic-guided	warfarin	and	clopidogrel	treatment,	particularly	since	
in	 recent	 years	 cardiology	 became	 the	 key	 medical	 specialty	 in	 which	
pharmacogenetics	applications	are	emerging	 into	practice.	Furthermore,	 in	 this	
thesis,	we	investigated,	through	structural	questionnaires,	the	views,	opinions	and	
attitudes	 of	 the	 various	 stakeholders	 and	 of	 the	 general	 public	 about	 genomic	
medicine	 and	 its	 impact	 to	 society.	 Lastly,	 we	 proposed	 an	 alternative	
methodological	approach	for	cost-effectiveness	analysis	and	developed	a	practical	
guidance	for	decision	making	by	budget	holders.	
In	 Chapter	 2,	 we	 provide	 some	 key	 examples	 of	 the	 applications	 of	
pharmacogenetics	 in	 modern	 medical	 practice,	 focusing	 on	 different	 medical	
specialties	such	as	cardiology,	oncology,	psychiatric	and	infectious	diseases	and	of	
these	interventions	that	have	been	approved	by	all	major	regulatory	bodies,	such	
as	 the	 US	 Food	 and	 Drug	 Administration	 (FDA)	 and	 the	 European	 Medicines	
Agency	(EMA).	Also,	we	emphasize	the	need	to	perform	economic	evaluation	and	
its	 different	 types,	 summarize	 the	 main	 methodological	 aspects	 of	 economic	
evaluation	 and	 outline	 the	 few	 examples	 of	 economic	 evaluation	 in	 genomic	
medicine	that	have	been	performed	so	far.	At	first,	we	aimed	to	determine	the	level	
of	 awareness	 of	 healthcare	 professionals	 in	 Greece	 with	 respect	 to	
pharmacogenetics	 and	 personalized	 medicine	 using	 structured	 questionnaires	
addressed	to	a	 large	number	of	pharmacists	and	physicians.	These	 findings	are	
presented	 in	 Chapter	 3,	 indicating	 that	 approximately	 60%	 of	 pharmacists	
consider	their	level	of	knowledge	of	personalized	medicine	to	be	very	low,	while	
over	half	of	the	pharmacists	and	physicians	indicate	that	they	would	be	unable	to	
explain	 the	 results	 of	 pharmacogenomic	 tests	 to	 their	 customers	 or	 patients,	
respectively.	 This	 situation	 may	 be	 directly	 related	 to	 the	 low	 level	 of	 their	
undergraduate	 education	 in	 genetics	 and	 pharmacogenomics.	 These	 findings	
provide	the	basis	for	assessing	the	views	of	healthcare	professionals	in	relation	to	





the	 clinic.	 To	 achieve	 our	 goals,	 we	 used	 the	 computerized	 version	 of	 the	
PolicyMaker	political	mapping	tool	to	collect	and	organize	important	information	
about	the	pharmacogenetics	and	genomic	medicine	policy	environment,	to	assess	










economic	 evaluation	 of	 genome-guided	warfarin	 treatment	 in	 elderly	 Croatian	
patients	suffering	from	atrial	fibrillation,	indicating	that	genome-guided	warfarin	
treatment	 is	 a	 cost-effective	 therapy	 option	 for	 the	 management	 of	 elderly	
patients	 with	 atrial	 fibrillation	 in	 Croatia.	 In	 particular,	 our	 primary	 analysis	
indicated	that	more	patients	(97.07%)	belonging	to	the	pharmacogenetics-guided	
group	did	not	have	any	major	 complications	as	 compared	 to	 the	 control	group	
(89.12%),	 while	 the	 total	 cost	 per	 patient	 was	 estimated	 at	 €538.7	 for	 the	
pharmacogenetics-guided	group	as	compared	to	€219.7	for	the	control	group.	In	
terms	 of	 QALYs	 gained,	 total	 QALYs	was	 estimated	 at	 0.954	 and	 0.944	 for	 the	
pharmacogenetics-guided	 and	 the	 control	 groups,	 respectively	 and	 the	
incremental	 cost-effectiveness	 ratio	 of	 the	 pharmacogenetics-guided	 vs	 the	
control	groups	was	estimated	at	€31,225/QALY.	
Similar	to	the	previous	chapter,	in	Chapter	6,	we	report	our	findings	from	
a	 retrospective	 study	 to	 assess	whether	CYP2C19-guided	genotyping	was	 cost-
effective	for	myocardial	infarction	patients	receiving	clopidogrel	treatment	in	the	
Serbian	 population	 compared	 to	 the	 non-genotype-guided	 treatment.	 Our	 data	
show	that	clopidogrel	treatment	coupled	with	CYP2C19-guided	genotyping	may	
represent	 a	 cost-saving	approach	 for	 the	management	of	myocardial	 infarction	
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patients	 undergoing	 primary	 percutaneous	 coronary	 intervention	 in	 Serbia.	 In	
particular,	we	 found	 that	 59.3%	of	 the	CYP2C19*1/*1	 patients	 had	 a	minor	 or	
major	 bleeding	 event	 versus	 42.85%	 of	 the	 CYP2C19*1/*2	 and	 *2/*2,	 while	 a	
reinfarction	event	occurred	only	in	2.3%	of	the	CYP21C9*1/*1	patients,	compared	
to	11.2%	of	the	CYP2C19*1/*2	and	CYP2C19*2/*2	patients.	The	mean	cost	for	the	
CYP2C19*1/*1	 patients	 was	 estimated	 at	 €2,547	 versus	 €2,799	 in	 the	
CYP2C19*1/*2	 and	 CYP2C19*2/*2	 patients,	 while,	 based	 on	 the	 overall	
CYP2C19*1/*2	genotype	frequencies	in	the	Serbian	population,	a	break-even	point	













resource	 allocation	 for	 genomic	 medicine,	 based	 on	 performance	 ratio,	 with	
potential	applications	in	diverse	health	care	sectors.	Similar	to	the	previous	model	
described	 in	 Chapter	 7,	 this	 model	 also	 addresses	 the	 needs	 of	 developing	
countries	and	low-resource	environments	and	takes	into	account	the	innovation	




































Het	 centrale	 doel	 van	 Personalised	 Medicine	 is	 om	 de	genetische	
informatie	van	het	 individu	 te	 gebruiken	 in	 het	 klinische	
besluitvormingsproces.		Hoewel	het	concept	van	gepersonaliseerde	geneeskunde	
relatief	 nieuw	 lijkt,	 bestaat	 de	 intellectuele	voorouder	ervan	 al	 geruime	 tijd.	Zo	




bijwerkingen	 van	 primaquine,	 een	 antimalariamiddel,	 beschreef	 bij	 een	 aantal	
soldaten	 die	 dit	 middel	 hadden	 voorgeschreven	 gekregen.	 Deze	 bijwerkingen	
bleken	 te	 zijn	 veroorzaakt	 door	 een	 genetisch	 defect	 in	 het	 glucose-6-fosfaat	
dehydrogenase	 (G6PD)	 enzym.	In	 1962	 beschreven	 Evans	 en	 collega's	 de	
genetische	 oorzaak	 van	 perifere	 neuropathie	 die	 optreedt	 wanneer	 patiënten	
werden	 behandeld	 met	 isoniazide,	 een	 middel	 tegen	 tuberculose,	 en	 brachten	
deze	 reactie	 in	 verband	 met	 genetische	 variaties	 in	 het	N-acetyl-transferase	
2(NAT2)	gen.	Een	belangrijke	bijdrage	op	het	gebied	van	de	farmacogenetica	was	
de	 ontdekking	 door	 Richard	 Smith	in	 1977	 over	 de	 genetische	 basis	 van	 de	 te	
sterke	 reactie	 op	 het	 antihypertensivum	 debrisoquine	 die	 sommige	 mensen	
hadden	ervaren.	Het	betrokken	enzym,	het	cytochroom	P450	2D6,	is	betrokken	bij	









De	 term	 voor	 dit	 veld	 van	 onderzoek	 is	 “farmacogenetica”,	 ofwel	
“pharmacogenetics”,		en	beschrijft	het	onderzoek	van	overerfbare	componenten	
en	 het	 metabolisme	 van	 geneesmiddelen.	 Later	 werd	 de	 term	
	196	




en	 in	 2015	 de	 nieuwste	 term	 “Precision	 Medicine”	 door	 de	 voormalige	
Amerikaanse	 president	 Barack	 H.	 Obama,	 in	 het	 kader	 van	 het	 Amerikaanse	
Precision	Medicine	Initiative	(PMI). 
Hoewel	 er	 veel	 definities	 van	 dit	 begrip	 zijn,	 omvat	 het	 concept	 van	




gezondheidszorgstelsels	 die	meer	 nadruk	 legden	 op	 het	 gebruik	 van	 evidence-

















overerfbare	 genetische	 variaties	 op	 geneesmiddelrespons,	 en	betreft	 zowel	het	
geneesmiddelmetabolisme	(farmacokinetiek)	alsook	de	geneesmiddelenwerking	
(farmacodynamiek).	Bovendien	 is	 aangetoond	 dat	 genetische	 varianten	 ook	
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verklaren	 dat	 wat	 voorheen	 werd	 beschouwd	 als	 idiosyncratische	
bijwerkingen	(adverse	 drug	 reactions:	 ADRs).	Met	 andere	 woorden,	 deze	
discipline	 heeft	 tot	 doel	 het	 beste	 geneesmiddel	 voor	 een	 specifieke	 ziekte	 te	
identificeren	 wanneer	 de	 ziekte	 voorkomt	 in	 een	 patiëntenpopulatie	 met	 een	
bepaald	 genotype.	Gezien	 het	 feit	 dat	 er	 genetische	 factoren	
zijn	die	verantwoordelijk	 zijn	 voor	 20-95%	 van	 de	 waargenomen	 reacties	 op	
medicamenteuze	therapieën,	zal	men	de	impact	van	deze	nieuwe	discipline	in	de	
moderne	geneeskunde	begrijpen.	Het	 is	belangrijk	om	op	te	merken	dat	andere	
factoren	 zoals	 leeftijd,	 dieet,	 -geneesmiddelinteracties	 en	 de	 aanwezigheid	 van	
andere	 ziekten	 (comorbiditeit)	 de	 geneesmiddelrespons	 van	 een	 individu	
beïnvloeden,	onafhankelijk	van,	in	combinatie	met	of	juist	in	additie	op	genetische	
factoren. 
Het	 doel	 van	 dit	 proefschrift	 is	 om	 de	 gezondheidsvoordelen	 van	
genoomgeleide	 behandelingsinterventies	 te	 beoordelen	 in	 vergelijking	 met	 de	
standaardinterventies	die	 in	de	huidige	medische	praktijk	worden	gebruikt.	We	
richten	 ons	 op	 de	 economische	 analyse	 van	 farmacogenetisch-geleide	
behandeling	 met	 warfarine	 en	 clopidogrel,	 vooral	 omdat	 de	 laatste	 jaren	
cardiologie	 het	 belangrijkste	 medische	 specialisme	 is	 geworden	
waarin	farmacogenetische	toepassingen	 in	 de	 praktijk	 worden	
toegepast.	Bovendien	hebben	we	in	dit	proefschrift,	door	middel	van	structurele	
vragenlijsten,	 de	 opvattingen,	 meningen	 en	 attitudes	 van	 de	 verschillende	
belanghebbenden	en	van	het	grote	publiek	over	genomische	geneeskunde,	en	de	
impact	 hiervan	 op	 de	 samenleving,	 onderzocht.	Tenslotte	 hebben	 we	 een	
alternatieve	methodologische	 benadering	 voor	 kosteneffectiviteits-
analyse	voorgesteld	en	een	praktische	 leidraad	ontwikkeld	voor	besluitvorming	
door	budgethouders. 
In	Hoofdstuk	 2	 geven	we	 enkele	 belangrijke	 voorbeelden	 van	 de	
toepassingen	van	farmacogenetica	in	de	moderne	medische	praktijk,	waarbij	we	
ons	 concentreren	 op	 verschillende	 medische	 specialismen	 zoals	 cardiologie,	
oncologie,	 psychiatrie	 en	 infectieziekten	 en	 die	 zijn	 goedgekeurd	 door	 alle	





evaluatie	 samen	 en	 we	 schetsen	 de	 schaarse	 voorbeelden	 van	 economische	
evaluaties	in	de	genomische	geneeskunde	die	tot	nu	toe	zijn	uitgevoerd.	In	eerste	
instantie	 wilden	 we	 bepalen	 in	 hoeverre	 gezondheidswerkers	 in	 Griekenland	
bekend	 zijn	 met	farmacogenetica	en	 Personalised	 Medicine,	 door	 middel	 van	
gestructureerde	vragenlijsten	die	aan	een	groot	aantal	apothekers	en	artsen	zijn	
voorgelegd.	Deze	bevindingen	worden	gepresenteerd	in	Hoofdstuk	3	,	waar	we	
aangeven	 dat	ongeveer	60%	 van	 de	 apothekers	 hun	 kennisniveau	 van	
Personalised	Medicine	als	“zeer	laag”	beschouwen,	terwijl	meer	dan	de	helft	van	de	
apothekers	 en	 artsen	aangeven	 dat	 ze	 niet	 in	 staat	 om	 de	 resultaten	 van	
farmacogenetische	testen	uit	te	leggen	aan	hun	klanten	of	patiënten.	Deze	situatie	
houdt	 mogelijk	rechtstreeks	 verband	 met	 het	 geringe	 niveau	 van	 hun	
vooropleiding	aangaande	(farmaco-)genetica.	Deze	bevindingen	vormen	de	basis	
voor	 het	 beoordelen	 van	 de	 mening	 van	 beroepsbeoefenaren	 in	 de	






we	 de	 geautomatiseerde	 versie	 van	 PolicyMake,	 een	 politieke	 mapping	 tool,	
gebruikt	 om	 belangrijke	 informatie	 over	 beleidsomgeving	van	
de	farmacogenetische	en	 genomische	 geneeskunde	 te	 verzamelen	 en	 te	




overgrote	 meerderheid	 van	 de	 belanghebbenden	 gemiddelde	 tot	 hoge	 steun	
uitspreekt	 aan	 de	 aanvankelijk	 gestelde	 doelen	 van	 de	 beleidsomgeving	 voor	
genomische	 geneeskunde.	Het	ministerie	 van	 Volksgezondheid	 en	 de	 openbare	
ziekenfondsen	 lijken	 hier	 echter	 tegen	 te	 zijn,	 hoogstwaarschijnlijk	 vanwege	
financiële	 beperkingen.	Deze	 bevindingen	 zouden	 bijdragen	 aan	 het	 aannemen	
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van	 die	beleidsmaatregelen	 die	 de	 acceptatie	 van	 genetica	 in	 conventionele	
medische	interventies	zullen	versnellen. 
In	Hoofdstuk	5	presenteren	we	onze	 bevindingen	 van	 een	prospectieve	
studie	om	een	economische	evaluatie	uit	te	voeren	van	genoomgeleide	warfarine-
behandeling	bij	oudere	Kroatische	patiënten	die	lijden	aan	atriumfibrilleren.	We	
laten	 zien	 dat	 genoomgeleide	 warfarine-
behandeling	een	kosteneffectieve	therapie	 is	voor	 de	 behandeling	 van	 ouderen	
patiënten	met	boezemfibrilleren	in	Kroatië.	Met	name	onze	primaire	analyse	gaf	
aan	 dat	 er	meer	 patiënten	 (97,07%)	 die	 tot	 de	 farmacogenetica-geleide	 groep	
behoren	 zonder	 belangrijke	 complicaties	 bleven,	 in	 vergelijking	 met	 de	
controlegroep	(89,12%	).	De	totale	kosten	per	patiënt	werd	geschat	op	€	538,70	






studie	 om	 te	 beoordelen	 of	een	 CYP2C19-geleide	therapie	 rendabel	 was	 voor	
myocardinfarct	patiënten	die	behandeld	worden	met	clopidogrel	in	vergelijking	
met	 een	 niet-genotype	 geleide	 behandeling	 in	 de	 Servische	 bevolking.	Onze	
gegevens	tonen	aan	dat	behandeling	met	clopidogrel,	in	combinatie	met	CYP2C19	







CYP2C19	*1/*2	 en	CYP2C19	*2/*2	 patiënten.	 Op	 basis	 van	 het	
algehele	CYP2C19*1/*2	 genotype	 frequenties	 in	 de	 Servische	
bevolking	toonde	een	break-even	 point-	analyse	 aan	 dat	 het	 uitvoeren	 van	 de	




genetica-gedreven	 benadering	 voor	 de	 volksgezondheid,	 om	 het	 klassieke	
besluitvormingsproces	in	de	gezondheidszorg	aan	te	passen	met	een	alternatieve	
methodologische	 benadering	 van	 kosteneffectiviteitsanalyse.	Hiervoor	
combineren	 we	 de	 klassieke	 kosteneffectiviteits-analyse	 met	




genomische	 geneeskunde,	 vooral	 in	 die	 landen	 met	 beperkingen	 qua	 budget,	
waardoor	 het	 bijzonder	 aantrekkelijk	 wordt	 om	 toe	 te	 passen	 in	
ontwikkelingslanden	 en	 in	 ontwikkelde	 landen	 voor	 low-income	
gezondheidszorginstellingen. 
Ten	 slotte	beschrijven	we	in	Hoofdstuk	8	een	nieuw	economisch	model,	
specifiek	 voor	 de	 toewijzing	 van	 middelen	 voor	 genomische	 geneeskunde,	
gebaseerd	 op	 prestatieverhouding,	 met	 mogelijke	 toepassingen	 in	 diverse	
sectoren	 van	 de	 gezondheidszorg.	Vergelijkbaar	 met	 het	 model	beschreven	
in	Hoofdstuk	7,	richt	dit	model	zich	ook	op	de	behoeften	van	ontwikkelingslanden	
en	gebieden	met	weinig	hulpbronnen	en	houdt	het	rekening	met	de	innovatie	en	



































































































































































26. Are	 you	 aware	 that	 in	 the	 drug	 label	 of	 certain	 drugs,	 undertaking	 of	 a	
pharmacogenomic	test	is	recommended	before	taking	the	drug	to	prevent	adverse	
reactions?	





30. An	 adequate	 regulatory	 and	 legal	 framework	 exists	 in	 the	 field	 of	 genetic	 tests	
(privacy	of	patients,	analysis	costs,	quality	accreditation	of	genetic	laboratories,	etc.)	
in	Greece.	











































































































































































































































































































































































































































































































































































Q26B.	 Are	 you	 aware	 that	 in	 the	 drug	 label	 of	 certain	 drugs,	 undertaking	 of	 a	
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Item	6	 –	Questionnaire	 distributed	 to	 the	 various	 stakeholders	 that	 have	
participated	in	the	study	
	












organizations	 	 	 	 	 	
Greek	bioethics	council	 	 	 	 	 	
Private	genetic	laboratories	 	 	 	 	 	
Religious	organizations	and	
church	 	 	 	 	 	
Consumers	and	citizens	 	 	 	 	 	
Pharmaceutical	and	
biotechnology	companies	 	 	 	 	 	
Genetics	and	genomics	
professional	associations	 	 	 	 	 	
Ministry	of	Health	 	 	 	 	 	
Payers	(Private	Health	
Insurance	Industry)	 	 	 	 	 	
Payers	(Public	Health	
Insurance	Funds)	 	 	 	 	 	
Other	private	companies	a	 	 	 	 	 	
Pharmacies	 	 	 	 	 	
Physicians	(Geneticists)	 	 	 	 	 	
Physicians	(others)	 	 	 	 	 	
Press	and	Media	 	 	 	 	 	
Private	providers	 	 	 	 	 	
Public	providers	 	 	 	 	 	
Greek	National	Medicines	




Question	 2:	 In	 your	 opinion,	 what	 is	 the	 intervention	 power	 of	 each	 of	 the	
following	stakeholders	to	influence	the	field	of	pharmacogenomics	and	genomic	
medicine?	
Stakeholders	 Low		 Medium		 High	
Academic	and	research	organizations	 	 	 	
Greek	bioethics	council	 	 	 	
Private	genetic	laboratories	 	 	 	
Religious	organizations	and	church	 	 	 	
Consumers	and	citizens	 	 	 	
Pharmaceutical	and	biotechnology	companies	 	 	 	
Genetics	and	genomics	professional	associations		 	 	 	
Ministry	of	Health	 	 	 	
Payers	(Private	Health	Insurance	Industry)	 	 	 	
Payers	(Public	Health	Insurance	Funds)	 	 	 	
Other	private	companies	a	 	 	 	
Pharmacies	 	 	 	
Physicians	(Geneticists)	 	 	 	
Physicians	(others)	 	 	 	
Press	and	Media	 	 	 	
Private	providers	 	 	 	
Public	providers	 	 	 	















































	 	 	 	 	 	 	
Greek	bioethics	council	 	 	 	 	 	 	 	
Private	genetic	laboratories	 	 	 	 	 	 	 	
Religious	organizations	and	
church	 	 	 	 	 	 	 	
Consumers	and	citizens	 	 	 	 	 	 	 	
Pharmaceutical	and	
biotechnology	companies	 	 	 	 	 	 	 	
Genetics	and	genomics	
professional	associations		 	 	 	 	 	 	 	
Ministry	of	Health	 	 	 	 	 	 	 	
Payers	(Private	Health	Insurance	
Industry)	 	 	 	 	 	 	 	
Payers	(Public	Health	Insurance	
Funds)	 	 	 	 	 	 	 	
Other	private	companies	a	 	 	 	 	 	 	 	
Pharmacies	 	 	 	 	 	 	 	
Physicians	(Geneticists)	 	 	 	 	 	 	 	
Physicians	(others)	 	 	 	 	 	 	 	
Press	and	Media	 	 	 	 	 	 	 	
Private	providers	 	 	 	 	 	 	 	
Public	providers	 	 	 	 	 	 	 	
Greek	National	Medicines	
Organization	









































Although	 coordinating	 policies	 across	 government	
ministries	 has	 always	 been	 a	 challenge,	 the	 benefits	












































































Health	 Economics	 and	 Decision	 Making	 (Pharmaceutical	 Price	 Regulation	 and	
Reimbursement,	 Economics	 for	 healthcare	 professionals,	 Health	 Economics,	
insurance)	and	also	in	the	organization	of	international	conferences.		
Christina	has	more	than	30	peer-reviewed	publications	and	book	chapters	in	high	
impact	 international	scientific	 journals	and	 international	 textbooks	and	she	has	
co-authored	 and	 co-edited	 two	 textbooks	 on	 Economic	 Evaluation	 in	 Genomic	
Medicine,	 published	 by	 Elsevier/Academic	 Press	 (Economic	 Evaluation	 in	
Genomic	 Medicine,	 ISBN	 978-0128014974;	 2015	 and	 Economic	 evaluation	 of	
Genomic	and	Precision	Medicine,	ISBN	9780128133828;	2020).	For	her	research	



































































































































































































































of	 health	 economics	 and	 economic	 evaluation	 in	 adopting	 personalized	 medicine	
interventions	and	expediting	their	incorporation	in	the	clinic,	as	well	as	his	convincing	me	
about	the	importance	of	embracing	this	discipline	which,	at	the	beginning	of	my	research	
work,	 was	 still	 in	 its	 infancy,	 had	 contributed	 decisively	 in	 my	 moving	 towards	 that	
direction	and	proven	to	be	 the	right	 thing	 to	do,	allowing	me	to	combine	my	previous	
experience	in	economics	for	the	needs	of	this	thesis.				

































patient’s	 life,	 in	 order	 to	 adjust	 the	 result	 according	 to	 patient	 quality	 of	 life.
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